etiolog
canin
lymphoma
larg
unknown
like
multifactori
howev
current
investig
shed
signific
light
subject
recent
advanc
molecular
cytogenet
see
chapter
section
includ
gene
microarray
techniqu
current
appli
investig
chromosom
aberr
dog
lymphoma
breen
group
document
gain
canin
chromosom
loss
chromosom
common
aberr
group
case
analyz
recent
public
canin
genom
commerci
avail
canin
gene
microarray
eg
genechip
canin
genom
array
affymetrix
santa
clara
california
certainli
lead
advanc
understand
genet
event
lymphoma
near
futur
sever
genet
predisposit
report
pedigre
bull
mastiff
group
relat
otter
hound
famili
rottweil
breed
pair
unrel
scottish
terrier
germ
line
somat
genet
mutat
tumor
suppressor
gene
see
chapter
nra
gene
document
bull
mastiff
dog
lymphoma
respect
addit
differ
preval
immunophenotyp
subtyp
lymphoma
among
differ
breed
shown
indic
herit
risk
epigenet
modif
also
investig
dog
lymphoma
deoxyribonucl
acid
dna
hypomethyl
see
chapter
section
featur
neoplast
cell
lymphoma
case
one
third
leukemia
case
investig
like
involv
malign
transform
lymphoid
cell
human
characterist
chromosom
abnorm
describ
increas
frequenc
precis
band
highresolut
techniqu
appli
chromosom
aberr
nonrandom
human
lymphoma
sever
aberr
serv
marker
variou
subtyp
lymphoma
addit
sever
oncogen
may
play
role
pathogenesi
lymphoma
detect
base
identif
cytogenet
abnorm
chromosom
aberr
also
report
canin
lymphoma
studi
dog
lymphoma
demonstr
treatment
advantag
dog
trisomi
chromosom
dog
studi
evidenc
increas
durat
first
remiss
overal
surviv
time
knowledg
molecular
event
tumorigenesi
expand
sever
molecular
aberr
implic
variou
canin
tumor
type
associ
lymphoma
identifi
alter
oncogenetumor
suppressor
gene
express
epigenet
chang
signal
transduct
deathpathway
alter
common
human
lymphoma
like
also
involv
dog
mention
earlier
nra
aberr
although
rare
dog
implic
dog
lymphoma
telomeras
activ
see
chapter
section
also
document
canin
lymphoma
tissu
alter
cellular
deathpathway
particularli
famili
proapoptot
antiapoptot
govern
molecul
implic
human
nonhodgkin
lymphoma
current
investig
canin
lymphoma
hypothesi
retroviru
may
involv
pathogenesi
canin
lymphoma
confirm
howev
viral
particl
properti
similar
retrovirus
identifi
shortterm
cultur
canin
lymphoma
tissu
physicianbas
oncolog
direct
associ
made
helicobact
infect
develop
gastric
lymphoma
although
shown
definit
dog
evid
indic
helicobact
infect
laboratori
beagl
result
gastric
lymphoid
follicl
format
consid
precursor
mucosaassoci
lymphoid
tissu
malt
lymphoma
human
evid
accumul
implic
phenoxyacet
acid
herbicid
particularli
acid
develop
human
nonhodgkin
lymphoma
popul
case
control
studi
nonhodgkin
lymphoma
kansa
farmer
report
twofold
sixfold
higher
risk
individu
frequent
mix
appli
herbicid
specif
publish
hospitalbas
case
control
studi
dog
indic
owner
household
dog
develop
malign
lymphoma
appli
herbicid
lawn
employ
commerci
lawn
care
compani
treat
yard
frequent
owner
dog
without
lymphoma
risk
canin
lymphoma
report
rise
twofold
odd
ratio
four
yearli
applic
result
studi
sinc
drawn
critic
three
followup
investig
valid
assert
increas
risk
anoth
studi
dog
expos
lawn
treatment
within
day
applic
time
like
urin
level
higher
highest
concentr
note
day
applic
studi
dog
lymphoma
tumor
dog
known
exposur
analyz
use
polymeras
chain
reaction
pcr
technolog
cellular
nra
oncogen
mutat
ra
gene
influenc
cell
prolifer
may
induc
differenti
signal
transduct
pathway
mutat
ra
gene
result
ra
protein
promot
cell
growth
one
dog
seri
show
mutat
nra
indic
mutat
uncommon
canin
lymphoma
find
similar
human
lymphoma
environment
case
control
studi
perform
europ
two
variabl
resid
industri
area
use
chemic
defin
paint
solvent
owner
modestli
increas
risk
lymphoma
howev
link
found
use
pesticid
risk
weak
associ
lymphoma
dog
exposur
strong
magnet
field
observ
preliminari
epidemiolog
studi
hospitalbas
case
control
studi
dog
categor
high
high
exposur
increas
risk
lymphoma
odd
ratio
thorough
studi
necessari
evalu
associ
impair
immun
function
identifi
dog
lymphoma
immun
system
alter
dog
eg
immunemedi
thrombocytopenia
independ
age
gender
associ
higher
risk
subsequ
develop
lymphoma
compar
normal
popul
addit
evid
role
immun
system
develop
lymphoma
come
observ
human
transplant
patient
individu
immunosuppress
higher
risk
lymphoreticular
cancer
organ
transplant
patient
higher
incid
nonhodgkin
lymphoma
case
lymphoma
develop
dog
treatment
cyclosporin
although
one
case
support
link
immunosuppress
therapi
speci
classif
malign
lymphoma
dog
distinguish
basi
anatom
locat
histolog
criteria
immunophenotyp
characterist
common
anatom
form
lymphoma
order
decreas
preval
multicentr
craniomediastin
gastrointestin
cutan
form
primari
extranod
form
occur
locat
outsid
lymphat
system
includ
eye
central
nervou
system
cn
bone
test
bladder
heart
nasal
caviti
eighti
percent
dog
lymphoma
develop
multicentr
form
distinguish
presenc
superfici
lymphadenopathi
figur
lymph
node
enlarg
usual
painless
rubberi
discret
may
local
initi
mandibular
prescapular
node
anim
asymptomat
time
present
approxim
histori
weight
loss
lethargi
anorexia
febril
episod
diffus
pulmonari
infiltr
also
may
seen
affect
dog
detect
radiograph
chang
figur
base
bronchoalveolar
lavag
actual
incid
lung
involv
may
higher
hepatosplenomegali
common
manifest
abdomin
involv
usual
associ
advanc
stage
multicentr
diseas
alimentari
form
lymphoma
much
less
common
usual
account
canin
lymphoma
form
report
common
male
dog
femal
dog
similar
observ
human
dog
infiltr
diseas
intestin
tract
show
weight
loss
anorexia
panhypoproteinemia
evid
malabsorpt
primari
gastrointestin
gi
lymphoma
dog
usual
occur
multifoc
diffus
throughout
submucosa
lamina
propria
small
intestin
frequent
superfici
ulcer
occasion
transmur
infiltr
serosa
lymphocyticplasmacyt
inflamm
seen
adjac
distant
primari
tumor
patholog
neoplasm
may
resembl
plasma
cell
tumor
aberr
product
immunoglobulin
may
occur
histopatholog
distinguish
gastrointestin
lymphoma
lymphocyticplasmacyt
enter
lpe
difficult
suggest
lpe
may
prelymphomat
chang
gi
tract
syndrom
immunoprolif
intestin
diseas
character
lymphocyticplasmacyt
enter
describ
basenji
subsequ
develop
gastrointestin
lymphoma
addit
plasma
cellrich
area
heterogen
lymphomat
infiltr
may
resembl
lesion
lpe
report
specif
identifi
immunophenotyp
lymphocyt
subpopul
alimentari
lymphoma
histor
presum
like
origin
b
cell
howev
recent
evid
suggest
gastrointestin
lymphoma
dog
origin
cell
boxer
sharpei
breed
appear
overrepres
alimentari
lymphoma
report
morpholog
featur
epitheliotrop
consist
tcell
diseas
later
thorac
radiograph
dog
diffus
interstiti
infiltr
lymphoma
secondari
multicentr
lymphoma
mediastin
form
lymphoma
occur
approxim
case
form
character
enlarg
craniomediastin
lymph
node
thymu
figur
howev
previous
note
dog
multicentr
lymphoma
radiograph
evid
craniomediastin
lymphadenopathi
hypercalcemia
report
occur
dog
lymphoma
common
mediastin
form
studi
dog
lymphoma
hypercalcemia
mediastin
lymphoma
mediastin
form
dog
commonli
associ
tcell
phenotyp
cutan
lymphoma
solitari
gener
usual
classifi
epitheliotrop
mycosi
fungoid
nonepitheliotrop
cutan
lymphoma
may
also
involv
oral
mucosa
extracutan
involv
occur
often
lymph
node
spleen
liver
bone
marrow
canin
epitheliotrop
cutan
lymphoma
common
form
cutan
lymphoma
usual
origin
cell
similar
develop
human
dog
cell
cell
wherea
human
mostli
cell
rare
form
cutan
tcell
lymphoma
character
gener
skin
involv
evid
circul
malign
cell
peripher
blood
lymphocyt
usual
larg
mm
diamet
fold
groov
nuclei
human
call
syndrom
also
report
dog
cat
bcell
cutan
lymphoma
usual
spare
epidermi
papillari
dermi
affect
middl
deep
portion
dermi
hepatosplen
lymphoma
rel
uncommon
distinct
present
dog
mark
lack
peripher
lymphadenopathi
face
hepat
splenic
bone
marrow
infiltr
malign
lymphocyt
usual
tcell
origin
biolog
form
lymphoma
extrem
aggress
poorli
respons
therapi
human
tumor
usual
compos
cell
ie
cell
express
receptor
immunophenotyp
confirm
least
one
dog
veterinari
literatur
intravascular
angiotroph
angioendotheliomatosi
lymphoma
distinct
form
lymphoma
defin
prolifer
neoplast
lymphocyt
within
lumen
wall
blood
vessel
absenc
primari
extravascular
mass
leukemia
report
sever
time
veterinari
literatur
case
involv
central
peripher
nervou
system
includ
eye
bcell
immunophenotyp
common
human
howev
report
case
dog
origin
either
cell
null
cell
neither
b
cell
although
one
case
bcell
phenotyp
report
lymphoma
aris
clonal
expans
lymphoid
cell
distinct
morpholog
immunophenotyp
featur
mani
histolog
system
use
classifi
nonhodgkin
lymphoma
nhl
human
appli
lymphoma
dog
speci
nation
cancer
institut
nci
work
formul
updat
kiel
system
adapt
canin
tumor
success
tabl
world
health
organ
also
publish
histolog
classif
scheme
use
revis
european
american
lymphoma
real
system
basi
defin
histolog
categori
hematopoiet
tumor
domest
anim
system
incorpor
histolog
immunohistolog
criteria
band
tcell
immunophenotyp
clinic
relev
system
like
high
howev
await
investig
recent
oncolog
committe
american
colleg
veterinari
pathologist
acvp
establish
lymphoma
subcommitte
formul
classif
system
lymphoma
clinic
relev
subcommitte
obtain
inform
intern
group
veterinari
oncologist
pathologist
report
expect
complet
work
formul
wf
develop
allow
investig
translat
among
numer
classif
system
clinic
trial
could
compar
human
larger
compil
agre
canin
lymphoma
intermedi
high
grade
howev
diffus
immunoblast
form
appear
predomin
unit
state
wherea
follicular
larg
cell
variat
predomin
europ
comparison
european
american
classif
warrant
base
discrep
wf
categor
tumor
accord
pattern
diffus
follicular
cell
type
eg
small
cleav
cell
larg
cell
immunoblast
includ
inform
immunophenotyp
tumor
wf
subtyp
relat
biolog
tumor
patient
surviv
updat
kiel
classif
includ
architectur
pattern
morpholog
centroblast
centrocyt
immunoblast
immunophenotyp
b
cell
cell
tumor
cell
system
tumor
categor
lowgrad
intermediategrad
highgrad
malign
lowgrad
lymphoma
compos
small
cell
low
mitot
rate
typic
progress
slowli
associ
long
surviv
time
incur
highgrad
lymphoma
high
mitot
rate
progress
rapidli
like
respond
chemotherapi
human
potenti
curabl
sever
featur
canin
lymphoma
becom
appar
wf
updat
kiel
classif
appli
strike
differ
canin
human
lymphoma
scarciti
follicular
lymphoma
dog
diffus
lymphoma
dog
initi
may
follicular
may
progress
aggress
diffus
form
time
diagnost
biopsi
small
percentag
canin
lymphoma
consid
lowgrad
tumor
lowgrad
small
cell
lymphoma
cell
origin
highgrad
lymphoma
occur
frequent
diffus
larg
cell
lymphoma
classifi
intermediategrad
wf
consid
highgrad
updat
kiel
classif
label
diffus
centroblast
lymphoma
canin
lymphoblast
lymphoma
uncommon
highgrad
lymphoma
bcell
origin
howev
document
differ
exist
preval
variou
lymphoma
immunophenotyp
base
breed
exampl
cocker
spaniel
doberman
pinscher
like
develop
bcell
lymphoma
boxer
like
tcell
lymphoma
golden
retriev
appear
equal
likelihood
band
tcell
tumor
clinic
use
classif
system
end
must
yield
inform
respons
therapi
mainten
remiss
surviv
studi
suggest
subtyp
wf
correl
surviv
kiel
system
may
use
predict
relaps
studi
highgrad
lymphoma
show
complet
respons
chemotherapi
significantli
often
lowgrad
tumor
howev
dog
lowgrad
tumor
may
live
long
time
without
aggress
chemotherapi
dog
tcell
lymphoma
shown
lower
rate
complet
respons
chemotherapi
shorter
remiss
surviv
time
dog
bcell
tumor
furthermor
tcell
lymphoma
tend
associ
hypercalcemia
veterinari
literatur
lymphoma
case
dog
bcell
lymphoma
tcell
lymphoma
account
mix
band
tcell
diseas
account
mani
null
cell
tumor
ie
neither
bcell
tcell
immunoreact
repres
fewer
develop
monoclon
antibodi
detect
specif
marker
canin
lymphocyt
made
immunophenotyp
tumor
dog
routin
avail
mani
commerci
laboratori
techniqu
also
perform
paraffinembed
sampl
cytolog
specimen
obtain
fineneedl
aspir
rappaport
classif
system
propos
human
nhl
describ
architectur
pattern
follicular
diffus
cytolog
featur
well
differenti
poorli
differenti
histiocyt
tumor
term
histiocyt
appli
tumor
lymphocyt
larger
diamet
vesicular
nuclei
promin
nucleoli
lymphocyt
undifferenti
lymphoma
also
use
malign
cell
morpholog
featur
benign
histiocyt
howev
immunophenotyp
fail
document
biolog
relationship
cell
true
histiocyt
therefor
term
larg
consid
misnom
furthermor
subgroup
histiocyt
lymphoma
includ
tumor
differ
morpholog
immunophenotyp
featur
rappaport
classif
use
provid
prognost
inform
guid
therapi
dog
lymphoma
low
number
follicular
tumor
dog
problemat
histiocyt
subgroup
failur
account
differ
morpholog
immunolog
cell
type
one
critic
classif
system
fail
includ
extranod
lymphoma
separ
categori
although
differ
nodal
extranod
tumor
biolog
behavior
prognosi
well
recogn
compar
inform
histogenesi
tumor
lack
exampl
human
small
cell
lymphoma
aris
malt
compos
cell
differ
immunophenotyp
small
cell
lymphoma
ie
malt
lymphoma
typic
neg
except
cutan
lymphoid
neoplasm
detail
character
extranod
lymphoma
dog
done
although
cutan
lymphoma
heterogen
group
neoplasm
includ
epitheliotrop
form
resembl
mycosi
fungoid
nonepitheliotrop
form
cutan
lymphoma
tcell
phenotyp
summar
import
determin
histolog
grade
canin
lymphoma
low
small
lymphocyt
centrocyt
lymphoma
intermedi
high
diffus
larg
cell
centroblast
immunoblast
lymphoma
furthermor
determin
immunophenotyp
tumor
provid
use
inform
respons
rate
chemotherapi
better
anim
bcell
tumor
intermediateto
highgrad
lymphoma
dog
lowgrad
lymphoma
long
surviv
time
without
aggress
therapi
clinic
sign
associ
canin
lymphoma
variabl
depend
extent
locat
tumor
multicentr
lymphoma
common
form
gener
painless
lymphadenopathi
see
figur
consist
find
addit
hepatosplenomegali
bone
marrow
involv
common
dog
multicentr
lymphoma
dramat
sign
system
ill
substag
box
howev
larg
array
nonspecif
sign
occur
anorexia
weight
loss
vomit
diarrhea
emaci
ascit
dyspnea
polydipsia
polyuria
fever
substag
b
dog
tcell
lymphoma
like
constitut
sign
ie
substag
b
polydipsia
polyuria
particularli
evid
dog
hypercalcemia
malign
dog
also
may
histori
clinic
sign
relat
blood
dyscrasia
secondari
mark
tumor
infiltr
bone
marrow
myelophthisi
paraneoplast
anemia
thrombocytopenia
neutropenia
sign
could
includ
fever
sepsi
anemia
hemorrhag
dog
gastrointestin
alimentari
lymphoma
usual
nonspecif
gi
sign
vomit
diarrhea
weight
loss
malabsorpt
mesenter
lymph
node
spleen
liver
may
involv
mediastin
form
lymphoma
character
enlarg
craniomediastin
structur
thymu
see
figur
clinic
sign
associ
extent
diseas
polydipsia
polyuria
hypercalcemia
patient
commonli
respiratori
distress
caus
spaceoccupi
mass
pleural
effus
exercis
intoler
possibl
regurgit
dog
mediastin
lymphoma
also
may
precav
syndrom
character
pit
edema
head
neck
forelimb
secondari
tumor
compress
invas
cranial
vena
cava
figur
sign
dog
extranod
lymphoma
depend
specif
organ
involv
cutan
lymphoma
usual
gener
multifoc
tumor
occur
nodul
plaqu
ulcer
erythrem
exfoli
dermat
epitheliotrop
tcell
lymphoma
eg
mycosi
fungoid
chronic
clinic
cours
three
appar
clinic
stage
initi
scale
alopecia
pruritu
seen
figur
diseas
progress
skin
becom
erythemat
thicken
ulcer
exud
final
stage
character
prolif
plaqu
nodul
progress
ulcer
figur
b
oral
involv
also
may
occur
appear
multicentr
erythemat
plaquelik
lesion
nodul
gum
lip
figur
c
dog
primari
cn
lymphoma
may
either
multifoc
solitari
involv
seizur
paralysi
paresi
may
note
ocular
lymphoma
character
infiltr
thicken
iri
uveiti
hypopyon
hyphema
posterior
synechia
glaucoma
figur
one
studi
case
canin
multicentr
lymphoma
ocular
chang
consist
lymphoma
seri
case
uveiti
dog
condit
occur
secondari
lymphoma
case
anterior
uveiti
often
seen
advanc
stage
diseas
stage
v
dog
intravascular
lymphoma
usual
sign
relat
cn
peripher
nervou
system
pn
ocular
involv
includ
paraparesi
ataxia
hyperesthesia
seizur
blind
lethargi
anorexia
weight
loss
diarrhea
polyuria
polydipsia
intermitt
fever
dog
pure
hepatosplen
lymphoma
usual
nonspecif
sign
lethargi
inappet
weak
differenti
diagnosi
lymphadenopathi
depend
dog
travel
histori
ie
rel
infecti
diseas
size
consist
locat
affect
lymph
node
caus
lymphadenopathi
includ
bacteri
viral
infect
parasit
toxoplasma
leishmania
spp
rickettsi
organ
salmon
poison
ehrlichia
sp
fungal
agent
blastomyc
histoplasma
spp
potenti
hypercalcemia
accompani
system
hormonelik
substanc
parathyroid
hormonerel
peptid
pthrp
elabor
neoplast
cell
howev
also
relat
product
sever
humor
factor
includ
tumor
necrosi
factoralpha
transform
growth
factorbeta
vitamin
analog
eg
sever
investig
report
hypercalcemia
dog
lymphoma
commonli
associ
tcell
lymphoma
paraneoplast
syndrom
may
encount
includ
monoclon
gammopathi
neuropathi
cancer
cachexia
anim
suspect
lymphoma
diagnost
evalu
includ
thorough
physic
examin
complet
blood
count
cbc
differenti
cell
count
includ
platelet
count
serum
biochemistri
profil
urinalysi
ultim
obtain
tissu
cytolog
specimen
definit
diagnosi
essenti
thorough
physic
examin
includ
palpat
assess
lymph
node
includ
palpabl
rectal
examin
author
experi
signific
proport
dog
rectal
polyp
consist
aggreg
neoplast
lymphocyt
mucou
membran
inspect
pallor
icteru
petechia
ulcer
sign
may
indic
anemia
thrombocytopenia
secondari
myelophthisi
immunemedi
diseas
may
evid
major
organ
failur
uremia
abdomin
palpat
may
reveal
organomegali
intestin
wall
thicken
mesenter
lymphadenopathi
thorac
auscult
may
reveal
presenc
mediastin
mass
pleural
effus
ocular
examin
includ
funduscop
assess
may
reveal
abnorm
uveiti
retin
hemorrhag
ocular
infiltr
approxim
one
third
one
half
dog
lymphoma
complet
blood
count
biochemistri
profil
urinalysi
anemia
common
lymphomarel
hematolog
abnorm
usual
normochrom
normocyt
nonregen
consist
anemia
chronic
diseas
howev
hemolyt
anemia
may
also
occur
regen
anemia
may
reflect
concomit
blood
loss
hemolysi
addit
signific
myelophthisi
present
anemia
may
accompani
thrombocytopenia
leukopenia
anim
anemia
evid
bleed
reticulocyt
count
platelet
count
coagul
studi
also
may
indic
thrombocytopenia
may
seen
case
bleed
seldom
clinic
problem
ie
stage
v
diseas
primari
lymphoblast
leukemia
discuss
later
import
prognos
entir
differ
hypoproteinemia
observ
often
anim
alimentari
lymphoma
dog
high
total
protein
evid
increas
globulin
fraction
chemistri
profil
serum
protein
evalu
serum
electrophoresi
monoclon
gammopathi
report
occur
approxim
dog
lymphoma
serum
biochem
abnorm
often
reflect
anatom
site
involv
addit
approxim
dog
lymphoma
hypercalcem
mediastin
involv
approxim
tcell
lymphoma
case
hypercalcemia
unknown
origin
lymphoma
alway
consid
high
differenti
diseas
list
diagnost
direct
possibl
undertaken
see
chapter
presenc
hypercalcemia
also
serv
marker
respons
therapi
elev
serum
urea
nitrogen
creatinin
occur
secondari
renal
infiltr
tumor
hypercalcem
nephrosi
preren
azotemia
dehydr
increas
liverspecif
enzym
activ
bilirubin
concentr
may
result
hepat
parenchym
infiltr
serum
globulin
elev
usual
monoclon
occur
infrequ
bcell
lymphoma
urinalysi
part
minimum
databas
use
assess
renal
function
urinari
tract
exampl
isosthenuria
proteinuria
absenc
activ
sediment
may
indic
renal
diseas
hematuria
may
result
hemostat
abnorm
import
rememb
isosthenuria
azotem
dog
hypercalcemia
necessarili
indic
renal
diseas
high
calcium
level
interfer
tubular
concentr
capabl
disrupt
antidiuret
hormon
adh
control
abnorm
serum
level
alpha
fetoprotein
glycoprotein
zinc
chromium
iron
endostatin
also
investig
dog
lymphoma
clinic
biolog
signific
alter
yet
elucid
morpholog
examin
tissu
cell
compris
tumor
essenti
diagnosi
lymphoma
care
taken
avoid
lymph
node
reactiv
area
eg
mandibular
lymph
node
prescapular
poplit
lymph
node
prefer
also
lymphoid
cell
fragil
prepar
smear
aspir
materi
gentl
pressur
appli
spread
materi
slide
case
diagnosi
lymphoma
made
evalu
fineneedl
aspir
affect
lymph
node
tissu
typic
cell
larg
lymphoid
cell
larger
neutrophil
may
visibl
nucleoli
basophil
cytoplasm
figur
fine
chromatin
indistinct
nucleoli
tissu
architectur
maintain
cytolog
specimen
effac
lymph
node
capsular
disrupt
detect
therefor
mark
reactiv
hyperplasia
character
increas
number
larg
lymphoid
cell
may
difficult
distinguish
lymphoma
small
cell
lymphoma
may
cytolog
clue
point
malign
also
classif
lymphoma
subcategori
compris
low
intermedi
highgrad
form
attempt
use
cytolog
appear
immunophenotyp
analysi
perform
accur
histolog
section
accur
histopatholog
evalu
entir
lymph
node
includ
capsul
remov
place
buffer
formalin
submit
pathologist
although
needl
core
biopsi
may
satisfactori
import
avoid
crush
artifact
inadequ
sampl
size
pathologist
prefer
whole
node
biopsi
provid
maximum
amount
inform
effac
normal
nodal
architectur
neoplast
lymphocyt
capsular
disrupt
characterist
find
figur
c
diagnost
ultrasonographi
ultrasoundguid
fineneedl
aspir
needl
biopsi
use
evalu
involv
liver
spleen
abdomin
lymph
node
possibl
diagnosi
made
sampl
peripher
node
avoid
percutan
biopsi
liver
spleen
howev
peripher
node
involv
appropri
biopsi
affect
tissu
abdomin
caviti
alimentari
lymphoma
open
surgic
wedg
biopsi
intestin
must
obtain
ideal
without
enter
intestin
lumen
adequ
tissu
must
obtain
import
difficulti
involv
differenti
lymphoma
lpe
endoscop
biopsi
may
inadequ
superfici
specimen
obtain
howev
aggress
endoscop
biopsi
techniqu
combin
accur
histopatholog
assess
improv
diagnost
yield
less
invas
techniqu
mani
dog
primari
gastrointestin
lymphoma
inflammatori
nonneoplast
infiltr
eg
lpe
may
misdiagnos
biopsi
specimen
superfici
cytolog
examin
cerebrospin
fluid
csf
thorac
fluid
aspir
intracavitari
mass
indic
anim
cn
diseas
pleural
effus
intrathorac
mass
respect
one
studi
dog
cn
involv
csf
analysi
diagnost
seven
eight
dog
characterist
csf
includ
elev
nucleat
cell
count
seven
dog
cell
atyp
lymphoid
cell
csf
protein
concentr
higher
five
seven
dog
rang
mgdl
refer
interv
less
mgdl
cutan
lymphoma
punch
biopsi
mm
taken
repres
infiltr
infect
skin
lesion
stage
procedur
cutan
lymphoma
vari
stage
shown
prognost
import
molecular
techniqu
use
establish
diagnosi
lymphoma
character
tumor
initi
diagnosi
made
tissu
cell
peripher
blood
lymph
node
site
analyz
histochem
cytochem
immunohistochem
immunocytochem
flow
cytometr
pcr
techniqu
exampl
tumor
immunophenotyp
b
cell
cell
prolifer
rate
eg
express
prolifer
cell
nuclear
antigen
pcna
argyrophil
nucleolar
organ
region
agnor
clonal
pcr
antigen
receptor
gene
rearrang
parr
determin
avail
analys
increas
although
current
immunophenotyp
consist
predict
prognosi
dog
part
iv
specif
malign
small
anim
patient
immunophenotyp
typic
use
determin
type
cell
make
lymphoma
sometim
techniqu
help
make
diagnosi
lymphoma
divers
popul
lymphocyt
expect
tissu
presenc
homogen
popul
immunophenotyp
support
neoplast
process
immunophenotyp
lymphocyt
identifi
determin
express
molecul
specif
b
cell
eg
cell
eg
although
tumor
cell
sometim
morpholog
characterist
typifi
particular
immunophenotyp
except
occur
morpholog
use
sole
determin
type
lymphocyt
exampl
seri
nine
highgrad
tcell
lymphoma
leukemia
dog
cell
plasmacytoid
appear
typic
associ
bcell
lymphoma
similarli
anatom
locat
alway
predict
immunophenotyp
seri
case
gastrointestin
lymphoma
dog
often
consid
neoplasm
b
cell
neoplast
cell
identifi
cell
posit
case
accur
determin
immunophenotyp
antibodi
lymphocyt
marker
appli
tissu
section
immunohistochemistri
cytolog
specimen
immunocytochemistri
individu
cell
fluid
medium
flow
cytometri
flow
cytometr
evalu
cell
needl
aspir
also
feasibl
cell
marker
includ
pan
helper
cytotox
b
cell
marker
see
figur
b
interestingli
aberr
express
cd
molecul
report
canin
lymphoma
studi
dog
lymphoma
tumor
cell
six
dog
posit
tand
bcell
cd
marker
howev
clonal
assay
discuss
later
reveal
clonal
either
tcell
immunoglobulin
receptor
indic
case
band
tcell
lymphoma
malign
cell
may
coexpress
band
tcell
cd
marker
antibodi
molecul
use
determin
immunophenotyp
howev
also
potenti
use
therapeut
modal
tumor
cell
could
target
use
antibodi
histolog
assess
marker
multidrug
resist
apoptot
pathway
eg
pglycoprotein
protein
current
evalu
dog
lymphoma
howev
signific
requir
evalu
clonal
assay
occasion
diagnosi
lymphoma
differenti
malign
vers
benign
prolifer
lymphocyt
possibl
base
standard
histolog
cytolog
criteria
case
advanc
molecular
analys
necessari
help
confirm
diagnosi
clonal
hallmark
malign
malign
cell
popul
theoret
deriv
expans
singl
malign
clone
character
particular
dna
region
uniqu
tumor
exampl
dog
tcell
lymphoma
malign
cell
dna
sequenc
variabl
region
tcell
receptor
tcr
gene
likewis
dog
bcell
lymphoma
tumor
cell
ident
dna
sequenc
variabl
region
immunoglobulin
receptor
gene
convers
reactiv
lymphocytosi
cell
polyclon
antigen
receptor
use
knowledg
investig
use
polymeras
chain
reaction
pcr
pcr
techniqu
amplifi
variabl
region
tcell
immunoglobulin
receptor
gene
detect
clonal
lymphocyt
popul
dog
figur
uniform
size
polymeras
chain
reaction
pcr
product
indic
clonal
panel
show
four
pcr
reaction
singl
dna
sampl
first
lane
left
panel
posit
control
indic
dna
present
nonrearrang
gene
would
appropri
target
reaction
middl
two
lane
repres
two
differ
reaction
amplifi
immunoglobulin
fourth
lane
show
amplif
sampl
separ
polyacrylamid
gel
lymph
node
aspir
normal
dog
b
lymph
node
aspir
dog
histolog
confirm
multicentr
bcell
lymphoma
c
lymph
node
aspir
dog
histolog
confirm
tcell
lymphoma
averi
pr
averi
ac
vet
clin
pathol
physicianbas
medicin
assay
clonal
approxim
sensit
fals
posit
rate
approxim
recent
studi
report
similar
rate
dog
fals
neg
fals
posit
result
occur
clonal
assay
exampl
cell
dog
lymphoma
may
neg
clonal
clonal
segment
dna
detect
primer
use
malign
cell
natur
killer
nk
cell
rare
malign
cell
present
low
frequenc
detect
fals
posit
result
occur
rare
infecti
diseas
ehrlichiosi
lyme
diseas
case
diagnosi
made
result
diagnost
test
consid
includ
histolog
cytolog
evalu
immunophenotyp
clonal
studi
conjunct
signal
physic
find
molecular
techniqu
addit
aid
diagnosi
could
also
use
determin
earli
recurr
accur
clinic
stage
socal
molecular
remiss
rate
sensit
standard
cytolog
assess
peripher
blood
bone
marrow
lymph
node
diagnosi
establish
extent
diseas
determin
correl
clinic
stage
diseas
stage
system
routin
use
stage
dog
lymphoma
present
box
dog
present
advanc
stage
stage
iii
iv
type
imag
assess
bone
marrow
involv
may
indic
stage
degre
thorough
stage
implement
depend
three
factor
whether
result
alter
treatment
plan
whether
relev
prognost
inform
gleam
whether
client
need
know
addit
differ
protocol
compar
respect
efficaci
consist
similar
stage
system
use
avoid
socal
stage
migrat
result
one
stage
methodolog
accur
anoth
effect
stage
migrat
current
evalu
veterinari
patient
lymphoma
concept
thoroughli
explor
impact
prognosi
consid
differ
publish
outcom
compar
bone
marrow
aspir
biopsi
proxim
humeru
iliac
crest
indic
complet
stage
dog
anemia
lymphocytosi
peripher
lymphocyt
atypia
peripher
cytopenia
one
studi
dog
lymphoma
circul
malign
cell
consid
leukem
wherea
bone
marrow
examin
indic
involv
dog
presenc
prolymphocyt
larg
lymphocyt
nucleoli
circul
dog
lymphoma
may
indic
bone
marrow
involv
import
rememb
cell
also
seen
gi
parasit
immunemedi
hemolyt
anemia
immunemedi
diseas
recent
circul
tumor
cell
dog
stage
iii
lymphoma
identifi
use
clonal
assay
parr
assay
sensit
routin
microscopi
detect
malign
cell
circul
correl
result
stage
prognosi
determin
bone
marrow
evalu
offer
prognost
valuabl
inform
client
commit
treatment
regardless
stage
diseas
necessari
evalu
thorac
abdomin
radiograph
may
import
determin
extent
intern
involv
approxim
dog
multicentr
lymphoma
abnorm
thorac
radiograph
one
third
evid
pulmonari
infiltr
two
third
thorac
lymphadenopathi
sternal
tracheobronchi
lymph
node
widen
cranial
mediastinum
see
craniomediastin
lymphadenopathi
detect
dog
lymphoma
abdomin
radiograph
reveal
evid
sublumbar
iliac
andor
mesenter
lymph
node
spleen
liver
involv
approxim
case
author
practic
typic
case
canin
multicentr
lymphoma
imag
limit
thorac
radiograph
prognost
differ
exist
dog
stage
iii
diseas
stage
iv
diseas
ie
liver
spleen
involv
howev
presenc
craniomediastin
lymphadenopathi
prognost
signific
see
prognosi
later
section
clinic
sign
attribut
abdomin
diseas
present
imag
abdomen
warrant
addit
state
previous
abdomin
ultrasonographi
import
obtain
ultrasoundguid
intraabdomin
sampl
diagnosi
also
use
diagnosi
gastrointestin
hepatosplen
lymphoma
advanc
imag
modal
includ
comput
tomographi
ct
magnet
reson
imag
mri
positron
emissioncomput
tomographi
petct
becom
commonplac
veterinari
practic
use
fulli
determin
therapeut
approach
particular
patient
lymphoma
determin
stage
substag
diseas
presenc
absenc
paraneoplast
diseas
patient
overal
physiolog
statu
financi
time
commit
client
client
level
comfort
regard
likelihood
treatmentrel
side
effect
canin
lymphoma
intermediateto
highgrad
tumor
histopatholog
character
play
less
import
role
determin
optim
treatment
without
treatment
dog
lymphoma
die
diseas
week
except
canin
lymphoma
consid
system
diseas
therefor
requir
system
therapi
achiev
remiss
prolong
surviv
system
chemotherapi
continu
therapi
choic
canin
lymphoma
gener
combin
chemotherapi
protocol
superior
efficaci
singl
agent
protocol
singl
agent
protocol
except
doxorubicin
lower
respons
rate
durabl
combin
chemotherapi
rare
case
lymphoma
limit
one
site
especi
extranod
site
anim
treat
local
modal
surgeri
radiat
therapi
long
caregiv
clinician
commit
dilig
reevalu
document
subsequ
system
involv
mani
chemotherapi
protocol
dog
lymphoma
develop
past
year
tabl
complex
combin
protocol
modif
chop
protocol
initi
design
human
oncolog
use
chop
repres
combin
cyclophosphamid
c
doxorubicin
repres
h
hydroxydaunorubicin
vincristin
oncovin
prednison
p
convent
chemotherapi
induc
complet
remiss
cr
approxim
dog
median
surviv
time
month
depend
protocol
use
approxim
dog
live
year
longer
initi
protocol
figur
respons
rate
durat
respons
vari
accord
presenc
absenc
prognost
factor
discuss
prognosi
section
cost
owner
depend
drug
drug
select
size
anim
frequenc
administr
laboratori
test
need
monitor
toxic
dog
respond
chemotherapi
achiev
complet
remiss
usual
free
clinic
sign
associ
lymphoma
subsequ
return
good
qualiti
life
treat
dog
lymphoma
gratifi
high
percentag
complet
respons
dog
toler
chemotherapi
well
experi
minor
dog
develop
signific
toxic
studi
assess
client
percept
medic
treatment
cancer
gener
lymphoma
particular
gener
report
posit
experi
owner
felt
treatment
worthwhil
result
improv
pet
wellb
anim
qualiti
life
treatment
good
client
express
regret
lymphoma
treat
multidrug
protocol
lymphoma
fundament
goal
chemotherapi
induc
complet
durabl
longer
month
first
remiss
induct
reinduc
remiss
tumor
recrudesc
patient
relaps
achiev
remiss
reinduct
final
induc
remiss
cancer
fail
respond
induct
reinduct
use
drug
present
standard
protocol
rescu
previous
unansw
question
treatment
lymphoma
whether
longterm
mainten
chemotherapi
use
initi
cours
aggress
induct
chemotherapi
last
month
less
longterm
mainten
chemotherapi
shown
ineffect
human
hodgkin
diseas
nhl
multipl
myeloma
howev
initi
induct
cours
chemotherapi
human
much
aggress
use
veterinari
patient
although
random
studi
perform
address
therapeut
benefit
longterm
mainten
chemotherapi
dog
comparison
dog
treat
chopbas
protocol
treatment
stop
month
induct
therapi
compar
sequenti
treat
histor
control
receiv
nearli
ident
protocol
includ
longterm
mainten
therapi
dog
receiv
shorten
less
expens
nomainten
protocol
compar
remiss
surviv
durat
like
achiev
second
remiss
relaps
complet
chemotherapi
counterpart
receiv
longterm
mainten
therapi
studi
although
prospect
random
trial
suggest
aggress
induct
discontinu
therapi
ie
induct
without
mainten
good
superior
protocol
use
extend
mainten
phase
data
taken
togeth
suggest
mainten
therapi
necessari
inde
may
inappropri
dog
lymphoma
treat
similar
combin
chemotherapi
protocol
singl
agent
chemotherapi
known
activ
dog
lymphoma
agent
includ
vinblastin
actinomycind
mitoxantron
chlorambucil
methotrex
dtic
ifosfamid
cytosin
arabinosid
gemcitabin
lomustin
cytosin
arabinosid
ifosfamid
gemcitabin
appear
minim
activ
except
doxorubicin
induct
singl
agent
chemotherapi
result
durabl
remiss
durat
compar
standard
combin
protocol
efficaci
incorpor
newer
drug
singl
agent
activ
standard
combin
protocol
await
investig
provid
precis
treatment
recommend
wide
varieti
clinic
set
dog
lymphoma
difficult
especi
light
plethora
publish
combin
drug
protocol
see
tabl
larg
ever
increas
number
protocol
avail
sever
factor
consid
discuss
caregiv
casebycas
basi
make
choic
protocol
factor
includ
cost
time
commit
efficaci
toxic
experi
clinician
protocol
question
increas
avail
gener
drug
protocol
becom
afford
larger
segment
veterinari
client
gener
complex
combin
chemotherapi
protocol
expens
timeconsum
ie
requir
repeat
offic
visit
closer
monitor
like
result
toxic
simpler
singl
agent
protocol
howev
gener
rule
complex
combin
protocol
result
longer
remiss
surviv
durat
singl
agent
protocol
earliest
treatment
protocol
use
veterinari
patient
nondoxorubicinbas
combin
chemotherapi
ie
cyclophosphamid
vincristin
prednison
cvp
rel
simpl
easi
protocol
welltoler
result
cr
rate
median
surviv
time
month
howev
clearli
establish
standard
care
combin
protocol
use
dog
lymphoma
includ
doxorubicin
essenti
variat
chop
protocol
previous
discuss
list
tabl
although
mani
chop
protocol
includ
lasparaginas
ad
either
initi
vari
time
throughout
protocol
sever
studi
confirm
addit
lasparaginas
induct
protocol
result
clinic
relev
increas
remiss
rate
speed
attain
remiss
firstremiss
durat
therefor
use
best
reserv
rescu
situat
discuss
later
regardless
veterinari
chopbas
combin
protocol
use
gener
result
cr
rate
median
surviv
time
month
dog
longterm
survivor
longer
year
cure
chop
protocol
use
author
time
public
box
gener
well
toler
dog
protocol
mainten
therapi
arm
treatment
stop
week
anim
complet
remiss
client
factor
consider
preclud
chopbas
protocol
singl
agent
doxorubicin
offer
altern
patient
receiv
five
doxorubicin
treatment
mgm
given
intraven
everi
week
expect
complet
respons
rate
rang
anticip
median
surviv
time
month
financi
client
concern
preclud
use
aggress
system
chemotherapi
prednison
therapi
alon
mgkg
given
oral
daili
often
result
shortliv
remiss
approxim
month
case
import
inform
client
decid
pursu
aggress
therapi
later
dog
previou
prednison
therapi
like
develop
multipl
drug
resist
mdr
receiv
singl
agent
prednison
shorter
remiss
surviv
durat
subsequ
combin
protocol
especi
true
longterm
prednison
therapi
dog
experienc
recurr
receiv
prednison
therefor
earlier
client
opt
aggress
therapi
like
durabl
respons
result
cbc
perform
chemotherapi
treatment
neutrophil
count
least
platelet
count
present
chemotherapeut
drug
administ
neutrophil
count
best
wait
day
repeat
cbc
count
risen
cellsml
drug
safe
administ
caveat
restrict
dog
present
initi
chemotherapi
low
neutrophil
platelet
count
bone
marrow
effac
myelosuppress
chemotherapi
institut
face
cytopenia
open
bone
marrow
allow
count
normal
regard
breed
like
gene
mutat
eg
colli
see
chapter
therefor
risk
seriou
unexpect
chemotherapi
toxic
author
initi
chop
protocol
sequenc
begin
drug
cyclophosphamid
ensur
treatment
lymphoma
allow
suffici
time
analysi
gene
mutat
see
chapter
drug
initi
eventu
dog
achiev
remiss
relaps
experi
recrudesc
lymphoma
usual
repres
emerg
tumor
clone
inher
resist
chemotherapi
origin
tumor
socal
mdr
clone
either
initi
drug
resist
becam
exposur
select
chemotherapeut
agent
evid
suggest
recurr
lymphoma
dog
tumor
cell
like
express
gene
encod
protein
transmembran
drug
pump
often
associ
multipl
drug
resist
caus
relaps
chemotherapi
includ
inadequ
dose
frequenc
administr
chemotherapi
failur
achiev
high
concentr
chemotherapeut
drug
certain
site
central
nervou
system
first
recurr
lymphoma
reinduct
attempt
first
reintroduc
induct
protocol
success
initi
special
attent
must
given
cumul
dose
doxorubicin
result
reinduct
also
baselin
cardiac
assess
use
cardioprotect
altern
drug
choic
client
educ
consid
gener
likelihood
respons
length
reinduct
half
seen
initi
therapi
howev
anim
enjoy
longterm
reinduct
especi
patient
complet
initi
induct
regimen
chemotherapi
relaps
occur
reinduct
rate
nearli
expect
dog
complet
chopbas
protocol
relaps
therapi
reinduct
fail
dog
respond
initi
induct
use
socal
rescu
agent
rescu
protocol
attempt
drug
drug
combin
typic
found
standard
chop
protocol
withheld
use
case
drug
resist
common
rescu
protocol
commonli
use
dog
includ
singl
agent
combin
use
actinomycin
mitoxantron
doxorubicin
doxorubicin
part
origin
induct
protocol
doxorubicindacarbazin
combin
lomustin
ccnu
lasparaginas
combin
mechlorethamin
vincristin
oncovin
procarbazin
prednison
mopp
overal
rescu
respons
rate
report
respons
usual
durabl
median
respons
time
month
typic
small
number
anim
enjoy
longer
rescu
durat
despit
plethora
publish
chemotherapi
protocol
dog
lymphoma
appear
veterinari
medicin
achiev
much
current
avail
chemotherapeut
drug
standard
set
dramat
improv
made
median
surviv
wall
surviv
rate
advanc
remiss
surviv
durat
await
develop
new
method
deliv
target
old
chemotherapeut
drug
develop
new
gener
chemotherapeut
novel
nonchemotherapeut
treatment
modal
mechan
avoid
abrog
mdr
enhanc
tumor
apoptosi
program
cell
death
target
treatment
immunoconjug
ie
antibodydirect
therapi
well
novel
immunomodulatori
therapi
activ
area
investig
human
veterinari
medicin
drug
resist
develop
cancer
patient
exposur
select
chemotherapeut
agent
often
associ
express
pglycoprotein
see
chapter
pglycoprotein
act
drug
efflux
pump
activ
extrud
drug
tumor
cell
prevent
cytotox
drug
reach
cellular
site
action
mdr
pglycoprotein
control
gene
mdr
report
canin
lymphoma
treatment
chemotherapi
one
studi
express
level
messeng
ribonucl
acid
mrna
encod
canin
gene
character
canin
cell
line
lymphoma
although
express
mrna
correl
vitro
drug
sensit
correl
vivo
doxorubicin
sensit
dog
lymphoma
studi
method
increas
time
tumor
cell
expos
chemotherapeut
drug
theoret
enhanc
tumor
kill
method
could
intralymphat
il
administr
autolog
kill
lymphoma
tumor
cell
vaccin
done
dog
remiss
achiev
combin
chemotherapi
protocol
studi
compar
dog
receiv
chemotherapi
il
vaccin
dog
receiv
chemotherapi
alon
median
remiss
time
day
respect
p
unfortun
surviv
time
two
group
significantli
differ
day
chemotherapi
plu
il
vaccin
day
chemotherapi
alon
dog
respond
signific
increas
specif
antibodi
lymphoma
antigen
compar
respond
anoth
immunotherapi
approach
involv
murinederiv
anticanin
monoclon
antibodi
antibodi
mediat
antibodydepend
cellular
cytotox
addc
complementmedi
cellular
cytotox
cmcc
prevent
outgrowth
canin
lymphoma
xenograft
nude
mice
noncontrol
clinic
studi
dog
treat
chemotherapi
lasparaginas
vincristin
cyclophosphamid
doxorubicin
two
cycl
chemotherapi
dog
achiev
complet
remiss
treat
intraven
infus
daili
day
median
surviv
time
dog
treat
day
surviv
rate
median
number
chemotherapi
cycl
first
year
three
median
number
cycl
antibodi
went
commerci
market
definit
random
trial
determin
effect
still
lack
dog
lymphoma
multicentr
form
need
system
chemotherapi
effect
treatment
diseas
howev
surgeri
use
treat
solitari
lymphoma
earli
stage
solitari
extranod
diseas
case
care
stage
necessari
rule
multicentr
involv
local
diseas
treat
benefit
surgic
remov
spleen
dog
massiv
splenomegali
remain
unclear
publish
report
dog
lymphoma
underw
splenectomi
massiv
spleen
subsequ
treat
chemotherapi
within
week
splenectomi
five
dog
die
dissemin
intravascular
coagul
dic
sepsi
remain
dog
complet
respons
rate
seven
follow
death
median
surviv
time
month
splenectomi
consid
lymphoma
remiss
site
splenic
enlarg
caus
lymphoma
respons
chemotherapi
dog
lymphoma
splenectomi
also
consid
treatment
uncontrol
hemolyt
anemia
persist
thrombocytopenia
role
radiotherapi
manag
lymphoma
dog
current
investig
use
whole
bodi
irradi
without
bone
marrow
transplant
yield
poor
result
howev
radiat
therapi
may
indic
select
case
indic
local
stage
stage
ii
diseas
ie
nasal
lymphoma
cn
lymphoma
palliat
local
diseas
eg
mandibular
lymphadenopathi
rectal
lymphoma
mediastin
lymphoma
accompani
precav
syndrom
local
bone
involv
whole
bodi
irradi
combin
bone
marrow
stem
cell
transplant
stage
halfbodi
irradi
chemotherapyinduc
remiss
use
stage
halfbodi
irradi
achiev
remiss
induct
chemotherapi
undergon
preliminari
investig
form
consolid
mainten
investig
radiat
therapi
deliv
either
cranial
caudal
half
dog
bodi
two
consecut
gray
daili
fraction
rest
week
half
bodi
irradi
similar
fashion
although
preliminari
investig
random
result
suggest
radiat
therapi
either
complet
chemotherapi
sandwich
chemotherapi
session
dog
either
complet
partial
remiss
safe
investig
extens
determin
whether
signific
therapeut
gain
could
realiz
gener
veterinari
literatur
offer
littl
inform
treatment
variou
extranod
form
lymphoma
dog
therefor
abil
predict
outcom
limit
author
recommend
extens
stage
local
therapi
eg
surgeri
local
radiat
therapi
use
case
diseas
local
solitari
site
multipl
extranod
site
involv
part
gener
process
system
chemotherapi
given
dog
alimentari
lymphoma
diffus
involv
intestin
tract
involv
local
lymph
node
liver
common
chemotherapi
dog
diffus
diseas
report
unreward
part
howev
author
experi
aggress
chopbas
protocol
use
extens
multicentr
lymphoma
dog
result
sever
case
durabl
remiss
alimentari
lymphoma
solitari
alimentari
lymphoma
rare
dog
tumor
local
remov
surgic
result
without
followup
chemotherapi
encourag
cn
lymphoma
dog
result
metastasi
multicentr
lymphoma
howev
primari
central
nervou
system
lymphoma
pcnsl
report
tumor
local
local
radiat
therapi
consid
studi
report
use
chemotherapi
one
studi
cytosin
arabinosid
arac
dosag
mgm
given
intrathec
bolu
inject
withdraw
equal
volum
csf
dose
dilut
ml
lactat
ringer
solut
inject
twice
weekli
total
six
treatment
treatment
combin
system
chemotherapi
cn
irradi
overal
respons
rate
low
short
durat
sever
week
month
treatment
cutan
lymphoma
depend
extent
diseas
solitari
lesion
may
treat
surgic
excis
radiat
therapi
fraction
radiat
therapi
total
dose
gy
associ
longterm
control
diffus
nontcel
lymphoma
best
manag
combin
chemotherapi
although
respons
rate
less
multicentr
lymphoma
one
studi
investig
report
combin
chemotherapi
cyclophosphamid
vincristin
oncovin
cytosin
arabinosid
prednison
coap
induc
longterm
remiss
case
five
six
dog
diffus
nontcel
cutan
lymphoma
attain
complet
partial
remiss
median
remiss
durat
longer
day
median
surviv
longer
day
retinoid
isotretinoin
accutan
etretin
tegison
use
success
canin
human
tcell
cutan
lymphoma
one
studi
dog
cutan
lymphoma
treat
isotretinoin
mgkg
given
oral
daili
two
treat
etretin
mgkg
given
oral
daili
continu
eleven
dog
tcell
cutan
lymphoma
six
dog
achiev
remiss
anoth
studi
four
dog
tcell
lymphoma
treat
success
isotretinoin
month
author
experi
retinoid
treatment
must
given
least
month
note
respons
polyethylen
glycol
peg
lasparaginas
mgkg
given
intramuscularli
weekli
induc
respons
dog
cutan
tcell
lymphoma
although
remiss
durabl
cure
note
prednison
may
also
necessari
control
pruritu
author
experi
pegylatedliposom
doxorubicin
doxil
produc
remiss
approxim
case
although
shortliv
respons
remiss
year
longer
occasion
occur
preliminari
abstract
report
activ
oral
ccnu
cutan
lymphoma
dog
seven
dog
five
mycosi
fungoid
mf
two
nonepitheliotrop
diseas
treat
ccnu
mgm
given
oral
everi
week
achiev
complet
respons
two
respons
rel
durabl
month
larger
cohort
need
treat
definit
respons
rate
durat
given
topic
chemotherapi
anoth
strategi
treat
cutan
tcell
lymphoma
although
rare
use
veterinari
medicin
patient
complianc
problem
mechlorethamin
mustargen
appli
topic
aqueou
solut
ointment
base
aqueou
solut
prepar
combin
mg
mechlorethamin
ml
tap
water
ointment
prepar
mix
mg
mechlorethamin
ml
absolut
alcohol
combin
enough
xipamid
aquaphor
prepar
g
ointment
hair
must
remov
applic
glove
must
use
drug
appli
mechlorethamin
carcinogen
caus
contact
hypersensit
human
respons
therapi
vari
treatment
often
palli
prognosi
canin
lymphoma
vari
depend
number
factor
locat
diseas
extent
diseas
clinic
stage
presenc
absenc
clinic
sign
substag
histolog
grade
immunophenotyp
cell
b
cell
exposur
previou
chemotherapi
corticosteroid
subsequ
develop
mdr
see
chapter
alter
cell
death
process
apoptosi
prolifer
rate
tumor
presenc
concurr
medic
problem
paraneoplast
condit
eg
hypercalcemia
weight
loss
liver
insuffici
possibl
gender
although
canin
lymphoma
rare
curabl
fewer
case
complet
respons
good
qualiti
life
extend
remiss
surviv
typic
factor
shown
influenc
surviv
shown
tabl
two
factor
consist
identifi
prognost
import
dog
lymphoma
immunophenotyp
substag
see
figur
mani
report
confirm
dog
tumor
ie
tcell
deriv
associ
significantli
shorter
remiss
surviv
durat
hold
true
primarili
dog
multicentr
lymphoma
immunophenotyp
solitari
extranod
form
lymphoma
thoroughli
investig
respect
prognosi
addit
shown
dog
bcell
lymphoma
express
lower
normal
level
antigen
express
nonneoplast
lymphocyt
also
shorter
remiss
surviv
durat
dog
substag
b
diseas
ie
clinic
ill
also
poorli
compar
dog
substag
adiseas
see
figur
dog
stage
stage
ii
diseas
better
prognosi
dog
advanc
diseas
stage
iii
iv
v
studi
elev
serum
calcium
mgdl
shown
neg
prognost
factor
howev
rare
hold
true
multivari
analysi
hypercalcemia
associ
tcell
phenotyp
histolog
grade
subtyp
found
influenc
prognosi
studi
howev
abil
predict
outcom
base
subtyp
still
quit
limit
dog
lymphoma
classifi
intermediateor
highgrad
larg
cell
centroblast
immunoblast
tend
respond
chemotherapi
relaps
earli
dog
lowgrad
lymphoma
small
lymphocyt
centrocyt
lower
respons
rate
chemotherapi
yet
surviv
advantag
dog
intermediateor
highgrad
lymphoma
figur
cours
diseas
may
indol
use
work
formul
dog
lowgrad
lymphoma
surviv
advantag
compar
dog
intermediateor
highgrad
tumor
recent
prolif
assay
eg
analysi
bromodeoxyuridin
brdu
uptak
antibodi
reactiv
agnor
indic
measur
prolif
activ
tumor
cell
shown
provid
signific
prognost
inform
dog
treat
combin
chemotherapi
howev
result
differ
studi
contradictori
two
trial
dog
tumor
short
doubl
time
high
agnor
frequenc
high
immunoreact
better
prognosi
dog
long
doubl
time
low
agnor
frequenc
trial
lowprolifer
tumor
group
associ
better
prognosi
one
trial
proport
tumor
cell
undergo
apoptosi
modestli
predict
remiss
durat
anatom
site
diseas
also
consider
prognost
import
primari
diffus
cutan
diffus
gastrointestin
hepatosplen
primari
cn
lymphoma
tend
associ
poor
prognosi
cutan
lymphoma
tend
progress
slowli
experi
respons
system
chemotherapi
less
durabl
local
lymphoma
skin
manag
radiat
therapi
surgeri
tumor
better
prognosi
dog
lymphoma
signific
involv
bone
marrow
may
present
ie
tumor
cell
compris
nucleat
cell
circul
malign
lymphocyt
may
present
peripher
blood
dog
tend
overal
poor
prognosi
case
difficult
determin
whether
diseas
aris
bone
marrow
eg
acut
lymphoblast
leukemia
diffus
lymphoma
extens
involv
marrow
immunophenotyp
help
case
tumor
cell
typic
posit
gender
shown
influenc
prognosi
studi
neuter
femal
tend
better
prognosi
male
may
higher
incid
tcell
phenotyp
may
account
poorer
prognosi
report
potenti
biomark
prognosi
includ
circul
level
glutathionestransferas
thymidin
kinas
vascular
endotheli
growth
factor
vegf
one
report
suggest
histori
chronic
inflammatori
diseas
sever
type
predict
likelihood
earli
relaps
put
prognost
indic
requir
confirm
larger
trial
lymphoid
leukemia
prolifer
neoplast
lymphocyt
usual
origin
bone
marrow
occasion
may
origin
spleen
neoplast
cell
may
may
circul
peripher
blood
lymphocyt
leukemia
common
nonlymphocyt
leukemia
myeloprolif
disord
mpd
true
incid
known
seri
case
german
shepherd
account
case
male
femal
f
ratio
studi
median
age
year
rang
year
eight
dog
younger
year
age
recent
report
greyhound
welldifferenti
chronic
lymphocyt
leukemia
cll
seen
less
frequent
commonli
mpd
median
age
year
f
ratio
report
dog
approxim
dog
granular
lymphocyt
gl
tcell
cll
larg
studi
dog
cll
gender
predilect
found
dog
bcell
nongl
cll
femal
dog
overrepres
among
dog
gl
cll
f
ratio
lymphoma
etiolog
lymphoid
leukemia
unknown
retrovirus
implic
divers
anim
speci
cat
cattl
fish
snake
bird
rodent
nonhuman
primat
retrovir
caus
dog
prove
howev
retroviru
morpholog
typic
lentivirus
isol
mononuclear
cell
obtain
peripher
blood
dog
human
acut
leukemia
associ
exposur
radiat
benzen
phenylbutazon
antineoplast
agent
alkyl
agent
caus
chromosom
damag
clearli
carcinogen
human
tlymphotrop
viru
type
proven
caus
leukemia
larg
cohort
human
patient
southern
island
japan
etiolog
cll
less
clear
genet
factor
like
import
extrapol
predispos
factor
across
speci
warrant
etiolog
factor
dog
may
quit
differ
human
given
differ
predomin
immunophenotyp
neoplast
cell
discuss
later
blast
cell
infiltr
bone
marrow
result
variabl
degre
anemia
thrombocytopenia
neutropenia
infiltr
spleen
liver
common
extramedullari
site
eg
nervou
system
bone
gi
tract
also
may
involv
anim
may
lymph
node
involv
develop
gener
lymphadenopathi
lymphocyt
cll
virtual
indistinguish
morpholog
normal
small
lymphocyt
low
prolifer
rate
accumul
lymphocyt
like
result
prolong
life
span
bcell
cll
marrow
infiltr
matur
lymphocyt
extent
infiltr
less
seen
mpd
neoplast
cell
gl
tcell
cll
origin
spleen
bone
marrow
involv
may
may
occur
dog
cll
tend
mild
anemia
granulocyt
platelet
mildli
reduc
splenomegali
common
lymph
node
slightli
moder
enlarg
despit
welldifferenti
appear
lymphocyt
cll
cell
may
function
abnorm
part
iv
specif
malign
small
anim
patient
paraneoplast
syndrom
includ
monoclon
gammopathi
immunemedi
hemolyt
anemia
pure
red
cell
aplasia
rare
hypercalcemia
hypercalcemia
report
giant
schnauzer
bcell
cll
highli
unusu
given
hypercalcemia
associ
tcell
lymphoprolif
disord
one
studi
dog
cll
monoclon
gammopathi
immunophenotyp
report
monoclon
gammopathi
associ
product
immunoglobulin
leukem
cell
b
cell
immunoglobulin
usual
igm
iga
term
macrogammaglobulinemia
use
describ
igm
gammopathi
see
chapter
section
dog
cll
igm
monoclon
gammopathi
said
macroglobulinemia
dog
also
develop
hyperviscos
syndrom
see
chapter
section
report
immunophenotyp
neoplast
cell
canin
leukemia
increas
frequenc
one
consist
find
acut
leukemia
either
acut
myeloid
leukemia
presenc
blast
cell
marker
use
distinguish
cll
lymphoma
bone
marrow
infiltr
one
studi
case
cll
eight
dog
associ
tcell
phenotyp
larger
studi
case
case
bcell
immunophenotyp
wherea
identifi
tcell
cll
tcell
leukemia
cell
morpholog
gl
find
difficult
reconcil
high
frequenc
monoclon
gammopathi
report
earlier
studi
also
note
differ
human
cll
typic
lymphoprolif
diseas
b
cell
dog
usual
histori
anorexia
weight
loss
polyuria
polydipsia
lethargi
splenomegali
typic
physic
abnorm
may
includ
hemorrhag
lymphadenopathi
hepatomegali
anemia
thrombocytopenia
elev
white
blood
cell
wbc
count
common
anemia
may
sever
usual
character
normocyt
normochrom
nonregen
wbc
count
usual
increas
despit
neutropenia
increas
number
circul
lymphoblast
cellsml
howev
dog
may
leukopen
neoplast
lymphoblast
may
infiltr
bone
marrow
extens
result
depress
normal
hematopoiet
element
dog
cll
often
asymptomat
although
owner
report
lethargi
decreas
appetit
mild
lymphadenopathi
splenomegali
may
present
dog
tend
mildli
anem
pack
cell
volum
pcv
less
thrombocytopen
plateletsml
wbc
count
usual
exce
cellsml
vari
normal
cellsml
owe
increas
circul
matur
lymphocyt
lymphocytosi
persist
granulocyt
usual
present
normal
number
dog
diseas
identifi
incident
patient
undergo
evalu
unrel
problem
clinician
must
consid
signal
histori
physic
find
cell
morpholog
immunophenotyp
diagnos
lymphoid
leukemia
accur
knowledg
profil
lymphocyt
subset
peripher
blood
normal
dog
help
determin
whether
particular
subset
expand
approxim
circul
lymphocyt
dog
cell
b
cell
nk
cell
doubleneg
cell
account
remain
fraction
tcell
fraction
helper
cell
outnumb
cytotox
cell
lymphocyt
leukemia
consider
atyp
lymphocyt
circul
immunophenotyp
lymphocyt
circul
homogen
phenotyp
typic
present
low
number
increas
differenti
diagnos
lymphocytosi
includ
certain
infecti
diseas
eg
chronic
ehrlichiosi
postvaccin
respons
young
dog
administr
transient
physiolog
epinephrineinduc
lymphocytosi
reactiv
neoplast
lymphocytos
sometim
difficult
differenti
case
pcr
assay
use
determin
clonal
cell
immunoglobulin
receptor
gene
popul
lymphocyt
see
earlier
discuss
infiltr
bone
marrow
neoplast
lymphoid
cell
hallmark
seen
case
cll
care
examin
peripher
blood
bone
marrow
experienc
cytopathologist
essenti
establish
diagnosi
lymphocyt
leukemia
adequ
diagnost
bone
marrow
obtain
aspir
bone
marrow
core
biopsi
perform
lymphoblast
predomin
bone
marrow
also
present
peripher
blood
infiltr
bone
marrow
lymphoblast
accompani
decreas
granulocyt
erythroid
megakaryocyt
cell
line
perhap
distinguish
featur
lymphoblast
nuclear
chromatin
pattern
condens
chromatin
myeloblast
lymphoblast
larger
neutrophil
high
nucleustocytoplasm
ratio
blue
cytoplasm
case
intens
basophil
figur
nucleoli
although
present
less
promin
lymphoblast
myeloblast
nevertheless
cell
easili
distinguish
blast
cell
hematopoiet
lineag
lineagespecif
marker
cell
must
identifi
immunocytochemistri
flow
cytometri
frequent
use
marker
cell
b
cell
mention
earlier
found
blast
cell
lymphoid
myeloid
lineag
posit
help
confirm
leukemia
immatur
cell
acut
leukemia
distinguish
stage
v
lymphoma
immatur
differenti
lymphocyt
may
stain
strongli
alkalin
phosphatas
activ
suggest
cytochem
stain
procedur
specif
myeloid
leukemia
bcell
nongl
tcell
cll
lymphocyt
small
matur
cell
figur
b
appear
excess
number
bone
marrow
nucleat
cell
earli
diseas
infiltr
becom
extens
diseas
slowli
progress
eventu
neoplast
cell
replac
normal
marrow
lymphoid
lineag
cell
cll
typic
easi
identifi
immunophenotyp
done
determin
lymphocyt
subset
dog
case
cll
tcell
prolifer
gl
cll
neoplast
cell
origin
spleen
separ
clinic
stage
system
develop
lymphocyt
leukemia
current
dog
leukemia
classifi
stage
v
base
stage
system
lymphoma
see
box
although
specif
clinic
stage
system
cll
use
human
evalu
dog
similar
infiltr
bone
marrow
malign
caus
morbid
suppress
bone
marrow
function
neutropenia
thrombocytopenia
anemia
may
sever
therapi
must
aggress
restor
hematopoiesi
logarithm
reduct
leukem
cell
number
less
million
cell
must
achiev
patient
need
support
therapi
fresh
whole
blood
broadspectrum
antibiot
fluid
therapi
nutrit
support
patient
must
monitor
care
bleed
thrombosi
may
signal
develop
dic
requir
aggress
chemotherapi
consist
efficaci
protocol
develop
veterinari
medicin
chopbas
protocol
similar
use
lymphoma
see
tend
use
treatment
protocol
dog
one
report
use
vincristin
prednison
dog
dog
respond
vincristin
prednison
complet
remiss
partial
remiss
addit
doxorubicin
lasparaginas
anticip
respons
rate
increas
previous
report
use
vincristin
prednison
alon
howev
rel
rariti
limit
abil
identifi
effect
protocol
b
indol
natur
cll
mani
anim
question
whether
dog
diseas
treat
controversi
oncologist
recommend
observ
activ
therapi
discoveri
cll
incident
physic
clinic
sign
present
signific
hematolog
abnorm
identifi
therapi
institut
anim
anem
thrombocytopen
show
evid
signific
lymphadenopathi
hepatosplenomegali
excess
high
wbc
count
lymphocytesml
box
effect
drug
evalu
thu
far
chlorambucil
chlorambucil
administ
dosag
mgkg
mgm
given
oral
daili
day
dosag
reduc
mgkg
mgm
given
oral
daili
longterm
mainten
dosag
mgm
given
oral
everi
day
use
dosag
adjust
accord
clinic
respons
bone
marrow
toler
chlorambucil
administ
without
food
increas
rate
absorpt
corticosteroid
lymphocytolyt
lead
cell
death
apoptosi
studi
human
shown
antitumor
activ
chlorambucil
combin
prednison
better
chlorambucil
alon
bone
marrow
heavili
infiltr
cll
cell
neutropenia
thrombocytopenia
anemia
occur
use
aggress
alkyl
agent
usual
cyclophosphamid
mgm
given
initi
oral
chlorambucil
prednison
therapi
consid
increas
speed
initi
remiss
howev
modif
protocol
scrutin
clinic
trial
chlorambucil
cyclophosphamid
fail
choic
treatment
combin
chemotherapi
similar
present
box
treatment
cll
primarili
palli
complet
remiss
rare
indol
natur
diseas
howev
surviv
time
rang
year
good
qualiti
life
human
splenectomi
shown
increas
surviv
significantli
individu
aggress
form
cll
howev
splenectomi
dog
cll
evalu
phenotyp
express
cll
usual
stabl
month
year
howev
diseas
may
evolv
acut
phase
dog
develop
rapidli
progress
pleomorph
immunoblast
lymphoma
human
call
richter
syndrom
prognosi
respons
treatment
poor
form
gener
prognosi
dog
poor
studi
dog
treat
vincristin
prednison
dog
achiev
complet
partial
remiss
median
surviv
time
day
dog
surviv
longer
month
protocol
one
case
report
dog
treat
infus
larg
volum
fresh
canin
plasma
whole
blood
complet
remiss
maintain
month
without
addit
therapi
unusu
respons
indic
normal
blood
contain
antileukem
factor
factor
state
cll
slowli
progress
diseas
anim
requir
therapi
one
dog
observ
almost
year
without
treatment
dog
treat
normal
wbc
count
expect
case
one
report
dog
treat
vincristin
chlorambucil
prednison
median
surviv
time
approxim
month
expect
surviv
year
studi
dog
treat
intermitt
chlorambucil
prednison
remiss
month
david
vail
lymphoma
malign
lymphoma
lymphosarcoma
divers
group
neoplasm
common
origin
lymphoreticular
cell
usual
aris
lymphoid
tissu
lymph
node
spleen
bone
marrow
howev
may
aris
almost
tissu
bodi
lymphoma
one
common
neoplasm
seen
cat
felin
leukemia
viru
felv
common
caus
hematopoiet
tumor
cat
socal
felv
era
lymphoma
case
associ
felv
antigenemia
sever
studi
document
potenti
molecular
mean
felv
result
lymphoid
neoplasia
howev
past
year
north
america
profound
chang
occur
viral
statu
present
signal
frequenc
anatom
site
cat
lymphoma
document
two
larg
studi
felin
lymphoma
involv
cat
chang
epidemiolog
characterist
lymphoma
cat
appear
coincid
widespread
integr
clinic
relev
felv
diagnost
assay
indirect
immunofluoresc
assay
affect
anim
elimin
regimen
late
enhanc
appear
commerci
avail
felv
vaccin
late
declin
felvassoci
lymphoma
mirror
declin
overal
preval
per
year
felv
posit
cat
test
character
report
tuft
veterinari
diagnost
laboratori
louweren
group
report
declin
felv
associ
case
lymphoma
cat
brought
univers
californiadavi
veterinari
teach
hospit
report
felv
antigen
repres
cat
lymphoma
incid
figur
felin
lymphoma
gener
use
felv
vaccin
test
becam
widespread
suggest
lymphoma
account
hematopoiet
tumor
cat
hematopoiet
tumor
lymphoid
myeloid
repres
approxim
one
third
felin
tumor
estim
incid
lymphoid
neoplasia
per
cat
risk
one
seri
cat
hematopoiet
tumor
lymphoma
leukemia
mpd
mpd
categor
undifferenti
leukemia
like
myeloid
origin
import
fact
louweren
studi
reveal
despit
sharp
drop
felvassoci
lymphoma
overal
preval
lymphoma
cat
increas
appear
due
increas
number
affect
cat
rel
frequenc
abdomin
particularli
intestin
anatom
form
lymphoma
speci
figur
might
expect
along
shift
away
felv
antigenassoci
tumor
came
shift
away
tradit
signal
rel
frequenc
anatom
site
observ
support
outsid
north
america
similar
signal
anatom
frequenc
data
obtain
australia
felv
infect
quit
rare
median
age
approxim
year
report
north
america
lymphoma
cat
consider
higher
median
age
year
report
felv
era
median
age
cat
within
variou
anatom
tumor
group
chang
anatom
form
tradit
associ
felv
mediastin
form
still
occur
younger
felvantigenem
cat
similarli
alimentari
form
occur
often
older
felvneg
cat
tabl
present
overview
characterist
variou
anatom
site
lymphoma
cat
younger
cat
lymphoma
tend
felv
antigenem
like
mediastin
multicentr
lymphoma
cat
spinal
lymphoma
also
felv
antigenem
older
cat
usual
felv
neg
develop
alimentari
lymphoma
larg
compil
australian
case
male
cat
siameseorient
breed
overrepres
similar
breed
find
observ
north
america
similar
gender
find
emerg
siameseorient
breed
appear
predisposit
mediastin
form
affect
younger
popul
median
age
year
evid
also
indic
felin
immunodefici
viru
fiv
infect
increas
incid
lymphoma
cat
contrast
felv
play
direct
role
tumorigenesi
fiv
appear
indirect
role
like
secondari
immunosuppress
affect
viru
shelton
colleagu
determin
fiv
infect
alon
cat
associ
fivefold
increas
risk
develop
lymphoma
coinfect
felv
potenti
develop
lymphoprolif
disord
experiment
cat
infect
fiv
develop
lymphoma
kidney
alimentari
tract
liver
multicentr
site
fivassoci
lymphoma
like
bcell
immunophenotyp
wherea
tcell
type
predominantli
associ
felv
suggest
fiv
infect
may
associ
often
alimentari
lymphoma
bcell
origin
may
relat
chronic
dysregul
immun
system
activ
oncogen
pathway
howev
anoth
larg
compil
case
fiv
antigenemia
rare
associ
alimentari
lymphoma
genet
molecular
factor
discuss
chapter
section
recent
advanc
molecular
cytogenet
see
chapter
section
includ
gene
microarray
techniqu
use
investig
chromosom
aberr
veterinari
speci
lymphoma
previous
mention
predisposit
orient
cat
breed
develop
lymphoma
suggest
genet
predisposit
indic
herit
risk
knowledg
molecular
event
tumorigenesi
expand
sever
molecular
aberr
implic
variou
felin
tumor
type
associ
lymphoma
identifi
alter
oncogenetumor
suppressor
gene
express
epigenet
chang
signal
transduct
deathpathway
alter
common
human
lymphoma
like
also
involv
cat
nra
aberr
although
rare
cat
implic
telomeras
activ
see
chapter
section
also
document
felin
lymphoma
tissu
factor
implic
felin
lymphoma
includ
alter
cellular
prolifer
cell
cycl
death
apoptosi
pathway
particularli
cyclindepend
kinas
cell
cycl
regul
famili
proapoptot
antiapoptot
govern
molecul
implic
human
nhl
environment
factor
evid
exposur
environment
tobacco
smoke
et
risk
factor
lymphoma
human
prompt
investig
cat
one
report
cat
exposur
et
rel
risk
develop
lymphoma
rel
risk
cat
year
exposur
immun
system
alter
cat
brought
fiv
infect
implic
develop
lymphoma
report
felin
renal
transplant
recipi
nearli
develop
de
novo
malign
lymphoma
bolster
support
link
immunosuppress
speci
find
similar
seen
immunosuppress
human
organ
transplant
patient
although
definit
proof
lack
grow
bodi
indirect
evid
suggest
lymphoma
may
associ
state
chronic
inflamm
intestin
nasal
lymphoma
particular
associ
suggest
intestin
lymphoma
inflammatori
bowel
diseas
howev
other
found
support
concept
addit
support
associ
provid
recent
report
suggest
cat
vaccin
siteassoci
sarcoma
syndrom
directli
link
inflamm
also
risk
develop
lymphoma
although
direct
evid
exist
link
diet
develop
intestin
lymphoma
cat
suggest
associ
support
rel
absolut
increas
intestin
form
lymphoma
past
year
fact
sever
dietari
modif
cat
food
occur
similar
time
frame
respons
condit
urinari
tract
diseas
investig
warrant
prove
disprov
assert
lymphoma
classifi
basi
anatom
locat
histolog
criteria
sever
system
anatom
classif
exist
lymphoma
cat
categor
diseas
mediastin
alimentari
multicentr
nodal
leukem
individu
extranod
form
other
combin
variou
nodal
extranod
form
categori
atyp
unclassifi
mix
still
other
combin
intestin
splenic
hepat
mesenter
nodal
form
one
categori
intraabdomin
purpos
discuss
mix
form
defin
case
involv
multipl
site
primari
site
categor
possibl
discrep
discuss
frequenc
inevit
result
variat
classif
use
literatur
rel
frequenc
anatom
form
immunophenotyp
may
vari
geograph
distribut
may
relat
genet
felv
strain
differ
well
preval
felv
vaccin
use
see
tabl
larger
studi
case
lymphoma
cat
approxim
bcell
immunophenotyp
howev
mediastin
leukem
pure
hepat
form
like
tcell
deriv
cat
cellrich
bcell
lymphoma
hodgkinslik
lymphoma
nklike
tcell
lymphoma
nont
nonbcel
describ
dog
lymphoma
cat
intermediategrad
highgrad
histolog
accord
work
formul
wf
criteria
alimentaryintestin
lymphoma
alimentaryintestin
lymphoma
manifest
pure
intestin
infiltr
combin
intestin
mesenter
lymph
node
liver
involv
report
limit
alimentari
form
gi
involv
without
extens
liver
approxim
two
third
three
fourth
report
case
bcell
immunophenotyp
patient
older
cat
case
appear
associ
felv
antigenemia
howev
discord
point
seen
literatur
one
smaller
report
alimentari
case
sampl
found
tcell
immunophenotyp
popul
size
rel
small
comparison
may
repres
geograph
variat
epitheliotrop
form
intestin
lymphoma
also
report
commonli
tcell
origin
canadian
group
investig
formalinfix
archiv
lymphoma
tissu
cat
found
nearli
even
distribut
bcell
tcell
immunophenotyp
also
found
approxim
two
third
sampl
felv
posit
pcr
techniqu
felvneg
tumor
may
deriv
transform
multipot
lymphoid
monocyt
precursor
fivtransform
b
lymphocyt
common
site
involv
alimentari
tract
small
intestin
case
follow
stomach
approxim
ileocecocol
junction
colon
tumor
solitari
diffus
throughout
intestin
figur
muscl
layer
intestin
submucosa
result
annular
thicken
lead
partial
complet
intestin
obstruct
seri
colon
neoplasia
part
iv
specif
malign
small
anim
patient
necropsi
specimen
cat
intestin
lymphoma
note
gener
thicken
small
intestin
associ
mesenter
lymph
node
involv
arrow
cat
lymphoma
second
common
malign
exceed
adenocarcinoma
abstract
report
describ
chronic
lymphocyticplasmacyt
enter
cat
progress
overt
lymphoma
month
conserv
therapi
mediastin
form
involv
thymu
mediastin
sternal
lymph
node
pleural
effus
common
two
larg
compil
cat
thymic
diseas
cat
pleural
effus
document
lymphoma
occasion
tumor
extend
thorac
inlet
palpat
ventral
neck
region
hypercalcemia
common
mediastin
lymphoma
dog
rare
cat
lymphoma
pthrp
detect
immunoradiometr
assay
cat
hypercalcemia
malign
includ
one
cat
lymphoma
cat
mediastin
lymphoma
young
felv
posit
tumor
tcell
immunophenotyp
involv
peripher
lymph
node
alon
unusu
cat
lymphoma
repres
approxim
case
contrast
approxim
one
fourth
anatom
form
lymphoma
degre
lymph
node
involv
one
third
cat
nodal
lymphoma
tcell
immunophenotyp
felv
antigenem
lymphoma
progress
bone
marrow
infiltr
malign
cell
hepatosplenomegali
may
develop
recent
uncommon
distinct
form
nodal
lymphoma
cat
refer
hodgkinslik
lymphoma
report
form
typic
involv
solitari
region
node
head
neck
histolog
resembl
hodgkin
lymphoma
human
tumor
gener
manifest
enlarg
singl
mandibular
cervic
node
immunophenotyp
classifi
cellrich
bcell
lymphoma
immunohistochem
analysi
none
associ
either
felv
fiv
sever
report
nonneoplast
peripher
lymphadenopathi
cat
publish
condit
resembl
lymphoma
clinic
histolog
featur
also
may
resembl
lymphoma
affect
lymph
node
may
two
three
time
normal
size
one
report
syndrom
call
distinct
peripher
lymph
node
hyperplasia
dplh
young
cat
cat
tend
young
year
old
mani
episod
fever
previou
viral
infect
may
hypergammaglobulinemia
polyclon
gammopathi
felv
neg
histopatholog
nodal
architectur
sever
distort
show
loss
subcapsular
medullari
sinus
cell
popul
show
admixtur
histiocyt
lymphocyt
plasma
cell
immunoblast
occasion
effac
lymphoid
follicl
lymph
node
regress
spontan
cat
histolog
chang
note
lymph
node
resembl
histolog
featur
acquir
immunodefici
syndrom
aid
relat
lymphadenopathi
human
anoth
report
benign
lymphadenopathi
cat
associ
argyrophil
intracellular
bacteria
common
extranod
site
lymphoma
kidney
nasal
caviti
eye
retrobulbar
space
cn
skin
renal
lymphoma
primari
associ
alimentari
lymphoma
base
sever
studi
median
age
cat
renal
lymphoma
approxim
year
one
fourth
case
felv
antigenem
bcell
immunophenotyp
frequenc
renal
lymphoma
report
approxim
lymphoma
extens
cn
common
sequela
renal
lymphoma
occur
treat
cat
nasalparanas
lymphoma
usual
local
diseas
howev
system
extens
occasion
seen
neoplasia
account
nonvir
nasalparanas
diseas
cat
lymphoma
report
repres
nearli
one
third
one
half
case
occur
primarili
older
felvneg
cat
median
age
year
least
three
fourth
case
b
cell
origin
intermedi
grade
high
grade
histolog
subset
epitheliotrop
tcell
nasal
lymphoma
report
cat
concurr
felv
posit
like
concurr
system
diseas
older
literatur
cn
lymphoma
often
seen
extradur
spinal
canal
felvposit
cat
howev
recent
review
spinal
cord
intracrani
lymphoma
occur
mostli
older
felvneg
cat
spinal
cord
site
commonli
intradur
extradur
meningioma
lymphoma
second
common
tumor
involv
cn
cat
felin
cn
lymphoma
may
primari
may
occur
secondari
multicentr
involv
especi
renal
system
bone
marrow
bone
involv
rare
seen
radiograph
multipl
cord
region
brain
involv
nearli
cat
spinal
lymphoma
patient
organ
eg
renal
bone
marrow
involv
one
third
case
intracrani
lymphoma
primari
confin
cn
cat
test
fiv
neg
cutan
lymphoma
gener
primari
seen
secondari
multicentr
involv
commonli
seen
older
cat
median
age
year
gender
sex
breed
predomin
found
although
patient
usual
felv
neg
one
case
report
use
pcr
techniqu
found
evid
felv
proviru
tumor
dna
cutan
lymphoma
solitari
gener
two
form
cutan
lymphoma
distinguish
histolog
immunohistochem
speci
epitheliotrop
form
sometim
refer
mycosi
fungoid
compos
lymphocyt
wherea
nonepitheliotrop
form
usual
compos
b
lymphocyt
contrast
one
report
nonepitheliotrop
cutan
lymphoma
cat
found
five
six
case
tcell
deriv
neoplast
lymphocyt
larg
abund
cytoplasm
convolut
nuclei
mycosi
cell
usual
form
intraepiderm
nest
five
cell
separ
surround
keratinocyt
clear
space
pautrier
microabscess
bcell
lymphoma
show
lymphocyt
deep
epidermi
spare
papillari
dermi
epidermi
recent
report
describ
case
cutan
lymphocytosi
uncommon
diseas
histolog
resembl
welldifferenti
lymphoma
solitari
lesion
common
compos
primarili
tcell
although
two
third
bcell
aggreg
cutan
lymphocytosi
character
slowli
progress
disord
intern
organ
infiltr
develop
case
cat
cutan
tcell
lymphoma
circul
atyp
lymphocyt
report
circul
cell
lymphocyt
larg
hyperchromat
groov
nuclei
human
cutan
tcell
lymphoma
circul
malign
cell
call
syndrom
also
report
dog
number
histopatholog
grade
system
use
classifi
human
nhl
includ
wf
discuss
earlier
chapter
recent
wf
use
classifi
case
felin
lymphoma
lowgrad
lymphoma
found
case
intermediategrad
diseas
highgrad
lymphoma
plasmacytoma
one
third
tumor
immunoblast
type
lymphoblast
lymphoma
subtyp
highgrad
tumor
account
less
similarli
larg
group
case
compil
australia
n
case
mediumto
highgrad
diseas
classifi
wf
also
discuss
earlier
chapter
publish
histolog
classif
scheme
use
revis
european
american
lymphoma
real
system
basi
defin
histolog
categori
hematopoiet
tumor
domest
anim
system
incorpor
histolog
criteria
immunohistolog
criteria
band
tcell
immunophenotyp
clinic
relev
system
like
high
howev
await
investig
evalu
seri
case
alimentari
lymphoma
highgrad
lymphoblast
type
howev
anoth
report
mani
intestin
lymphoma
sever
characterist
malt
describ
human
tendenc
remain
local
lamina
propria
rel
indol
clinic
behavior
excess
lowgrad
tumor
age
affect
anim
vari
consider
variou
subtyp
gener
lowgrad
tumor
tend
develop
older
cat
year
age
highgrad
tumor
tend
develop
younger
cat
year
age
less
commonli
report
distinct
form
alimentari
lymphoma
describ
classifi
larg
granular
lymphoma
lesion
granul
round
cell
tumor
also
call
either
globul
leukocyt
tumor
larg
granular
lymphocyt
lymphoma
although
probabl
variat
diseas
larg
granular
lymphocyt
character
abund
cytoplasm
promin
azurophil
granul
popul
cell
includ
nk
cell
cytotox
cell
sever
report
identifi
immunophenotyp
perforin
posit
neg
cell
also
describ
tcell
receptor
gene
rearrang
tumor
commonli
origin
small
intestin
especi
jejunum
mesenter
lymph
node
howev
case
show
widespread
metastasi
lung
myocardium
salivari
gland
spinal
cord
leukemia
also
report
diseas
affect
cat
gener
felv
neg
larg
granular
lymphocyt
must
differenti
sever
granular
cell
type
may
found
small
intestin
includ
enterochromaffin
cell
mast
cell
eosinophil
clinic
sign
associ
felin
lymphoma
vari
depend
locat
extent
diseas
alimentari
form
commonli
associ
abdomin
mass
origin
gi
tract
condit
often
associ
enlarg
mesenter
lymph
node
organ
involv
case
palpabl
abdomin
mass
thicken
bowel
loop
present
clinic
sign
may
consist
weight
loss
anorexia
diarrhea
occasion
vomit
approxim
half
case
histor
find
anorexia
weight
loss
report
present
includ
abdomin
distent
splenomegali
persist
thrombocytopenia
pica
hematochezia
tenesmu
may
present
lymphoma
involv
colon
polyuria
polydipsia
report
approxim
case
small
percentag
case
patient
may
sign
consist
acut
abdomen
result
intestin
perfor
concurr
periton
clinic
sign
mediastin
form
lymphoma
includ
dyspnea
tachypnea
noncompress
anterior
mediastinum
dull
heart
lung
sound
rare
case
horner
syndrom
may
present
result
involv
sympathet
nerv
ascend
around
first
rib
edema
head
may
caus
pressur
cranial
vena
cava
pleural
effus
common
pleural
fluid
character
serohemorrhag
chylou
effus
case
neoplast
cell
lymphoblast
identifi
cat
nodal
form
lymphoma
variabl
clinic
sign
depend
locat
extent
diseas
howev
cat
often
depress
letharg
peripher
lymphadenopathi
physic
find
uncommon
present
cat
state
earlier
uncommon
distinct
form
nodal
lymphoma
cat
hodgkinslik
lymphoma
form
typic
involv
singl
mandibular
cervic
node
cat
usual
overt
clinic
sign
cat
unlik
dog
peripher
lymphadenopathi
without
organomegali
often
hyperplast
reactiv
repres
lymphoma
extranod
site
includ
kidney
skin
eye
nasal
area
cn
renal
lymphoma
consist
bilater
even
cat
appear
unilater
diseas
gener
kidney
uniformli
enlarg
howev
may
also
feel
lumpi
irregular
palpat
cat
sign
consist
renal
insuffici
cat
cn
lymphoma
often
sign
associ
thoracolumbar
involv
common
site
second
thorac
fourth
lumbar
vertebra
sign
includ
gradual
sudden
onset
weak
upper
motor
neuron
paralysi
bladder
tail
flaccid
hyperpathia
region
lesion
progress
ataxia
neurolog
dysfunct
may
insidi
may
progress
rapidli
cat
cervic
spinal
cord
nerv
root
involv
gener
show
peracut
tetraparesi
diminish
sensat
thorac
limb
cervic
root
involv
may
show
root
lesion
root
signatur
lame
hyperesthesia
upon
shoulder
extens
common
present
sign
intracrani
lymphoma
decreas
order
frequenc
includ
anorexia
ataxia
lethargi
alter
conscious
aggress
cat
nasal
lymphoma
usual
sign
local
nasal
passag
larg
compil
case
present
complaint
decreas
order
frequenc
unilater
nasal
discharg
bilater
less
common
facial
deform
dyspnea
epistaxi
stertor
anorexia
epiphora
exophthalmia
sneez
region
lymphadenopathi
also
occur
cutan
lymphoma
may
solitari
diffus
manifest
alopecia
erythema
crust
papul
minim
peripher
lymphadenopathi
may
also
present
cat
sign
prolong
durat
ie
sever
month
nonspecif
sign
cat
lymphoma
regardless
site
may
secondari
bone
marrow
infiltr
lead
anemia
leukem
blood
profil
anemia
common
condit
cat
lymphoma
least
moder
sever
nonregen
anemia
sign
relat
paraneoplast
hypercalcemia
pupd
occur
cat
syndrom
much
less
common
dog
one
survey
hypercalcemia
cat
approxim
diagnos
lymphoma
variou
anatom
type
one
case
hypereosinophil
paraneoplast
syndrom
one
case
symmetr
cutan
necrosi
report
cat
lymphoma
number
diseas
condit
confus
lymphoma
cat
tabl
cat
suspect
lymphoma
leukemia
diagnost
evalu
includ
cbc
differenti
cell
count
platelet
count
serum
chemistri
profil
test
felv
fiv
bone
marrow
aspir
biopsi
may
indic
evalu
possibl
involv
complet
stage
extent
diseas
bone
marrow
evalu
particularli
indic
anemia
cellular
atypia
leukopenia
present
histopatholog
evalu
lymph
node
involv
organ
tissu
procur
mean
surgic
incis
endoscopi
needl
core
biopsi
essenti
definit
diagnosi
cat
lymph
node
fineneedl
aspir
alon
suffici
case
difficulti
involv
distinguish
lymphoma
benign
hyperplast
lymph
node
syndrom
uniqu
speci
includ
idiopath
peripher
lymphadenopathi
plexiform
vascular
lymph
node
peripher
lymph
node
hyperplasia
young
cat
whole
lymph
node
excis
prefer
case
determin
orient
invas
architectur
abnorm
may
necessari
diagnosi
addit
sitespecif
cytolog
histolog
assess
may
warrant
extranod
site
suspect
histolog
cytolog
sampl
also
analyz
variou
histochem
immunohistochem
techniqu
determin
immunophenotyp
b
cell
cell
tumor
prolifer
rate
eg
pcna
agnor
telomeras
activ
see
chapter
section
histolog
subtyp
low
intermedi
high
grade
avail
analysi
increas
current
none
prove
predict
outcom
cat
serum
chemistri
profil
help
establish
overal
health
clinic
stage
cat
result
specif
diagnosi
elev
liver
enzym
may
indic
hepat
infiltr
lymphoma
elev
blood
urea
nitrogen
bun
creatinin
level
may
indic
renal
lymphoma
cat
alimentari
lymphoma
hypoproteinemia
anemia
report
occur
case
respect
hypercalcemia
rare
cat
report
patient
lymphoma
variou
anatom
site
elev
globulin
level
may
indic
presenc
monoclon
gammopathi
without
serum
hyperviscos
rare
report
paraneoplast
syndrom
cat
lymphoma
hypoglycemia
report
approxim
one
third
cat
lymphoma
australian
studi
serum
alpha
glycoprotein
concentr
report
elev
cat
lymphoma
clinic
relev
associ
find
cat
alimentari
lymphoma
develop
palpabl
abdomin
mass
thicken
intestin
loop
approxim
one
third
patient
mass
visual
abdomin
radiograph
ultrasound
abnorm
ultrasound
abnorm
may
includ
mesenter
lymphadenopathi
case
intestin
mass
thicken
approxim
case
possibl
splenomegali
approxim
cat
ultrasonograph
chang
spleen
lymphoma
hepatomegali
effus
one
compil
case
lesion
appear
ultrasonograph
local
case
diffus
howev
surgeri
resect
alimentari
lymphoma
especi
primari
gi
lymphoma
suspect
caution
must
exercis
endoscop
obtain
tissu
use
difficulti
differenti
lymphoplasmacyt
gastroenter
primari
diffus
intestin
lymphoma
howev
diagnosi
diseas
mean
endoscop
deriv
biopsi
improv
advanc
techniqu
instrument
wedg
biopsi
serosa
musculari
avoid
mucosa
may
necessari
establish
diagnosi
case
endoscop
sampl
equivoc
altern
nearli
half
alimentari
lymphoma
secondari
mesenter
lymph
node
involv
ultrasoundguid
biopsi
specimen
fineneedl
aspir
may
adequ
diagnosi
cat
mediastin
lymphoma
diagnost
suspicion
may
begin
noncompress
cranial
thorax
physic
examin
conform
mediastin
mass
pleural
effus
thorac
radiograph
figur
fineneedl
aspir
suspect
mass
cytolog
evalu
pleural
fluid
may
suffici
establish
diagnosi
cat
find
monoton
popul
lymphoblast
establish
diagnosi
howev
definit
diagnosi
lymphoma
cat
mediastin
mass
concurr
chylothorax
challeng
ct
appear
lesion
chylou
effus
pleural
fluid
triglycerid
concentr
greater
serum
howev
anorect
cat
lower
triglycerid
level
pleural
fluid
major
differenti
diagnosi
mediastin
lymphoma
thymoma
cytolog
featur
thymoma
recent
describ
although
found
distinct
lymphoma
mani
case
diagnosi
challeng
preponder
small
lymphocyt
thymoma
mast
cell
also
seen
aspir
sampl
thymoma
diagnost
extranod
form
lymphoma
site
specif
cat
suspect
spinal
lymphoma
survey
radiograph
spine
rare
reveal
osseou
lesion
myelogram
ct
mri
indic
approxim
case
extradur
intradur
mass
detect
lesion
occur
thoracolumbar
lumbosacr
locat
fluoroscopicguid
fineneedl
aspir
epidur
lesion
may
yield
enough
tissu
cytolog
diagnosi
cat
evalu
one
studi
csf
analysi
reveal
clear
colorless
fluid
mix
pleocytosi
mean
rang
cellsul
elev
protein
content
mean
mgdl
rang
mgdl
malign
lymphocyt
identifi
six
cat
evalu
csf
analysi
report
intracrani
neoplasia
one
two
cat
lymphoma
lymphoblast
csf
fluid
bone
marrow
renal
involv
common
cat
suspect
cn
lymphoma
cytolog
assess
organ
gener
easier
spinal
site
nasal
lymphoma
suspect
biopsi
specimen
obtain
either
intranas
procur
flush
one
hemicav
bulb
syring
salin
occlud
contralater
caviti
collect
sampl
flush
nasopharynx
figur
thorough
stage
make
sure
diseas
confin
nasal
passag
recommend
present
treat
local
radiotherapi
system
involv
rule
ct
scan
indic
determin
local
involv
plan
radiotherapi
pursu
cutan
lymphoma
punch
biopsi
mm
taken
repres
infiltr
site
although
overtli
infect
skin
lesion
avoid
complet
stage
rule
system
diseas
also
recommend
cat
cutan
lymphoma
local
therapi
appli
case
solitari
diseas
case
renal
lymphoma
physic
examin
find
massiv
often
bilater
renomegali
rais
index
suspicion
radiograph
appear
smooth
irregular
renomegali
figur
consist
either
renal
lymphoma
polycyst
kidney
diseas
diseas
usual
diffus
throughout
renal
cortex
figur
b
transabdomin
needl
aspir
core
biopsi
diagnost
case
stage
system
exist
cat
similar
one
use
dog
see
box
howev
high
incid
viscer
involv
felin
speci
anoth
stage
system
use
often
box
lymphoma
cat
vari
respect
locat
anatom
type
stage
system
gener
less
help
predict
respons
occasion
diagnosi
lymphoma
differenti
malign
benign
prolifer
lymphocyt
possibl
base
standard
histolog
cytolog
criteria
case
advanc
molecular
analys
may
help
confirm
diagnosi
clonal
hallmark
malign
malign
cell
popul
theoret
deriv
expans
singl
malign
clone
discuss
earlier
chapter
lymphoma
dog
see
section
figur
assay
appli
advanc
diagnosi
lymphoma
cat
investig
use
pcr
techniqu
amplifi
variabl
region
tcell
immunoglobulin
receptor
gene
detect
clonal
lymphocyt
popul
cat
techniqu
appear
use
adjunct
diagnost
tool
although
undergo
thorough
assess
molecular
techniqu
may
also
prove
use
assess
earli
recurr
accur
clinic
stage
provid
socal
molecular
remiss
rate
sensit
standard
cytolog
assess
peripher
blood
bone
marrow
lymph
node
knowledg
base
treat
cat
lymphoma
less
well
establish
less
predict
dog
primarili
greater
variat
histolog
type
anatom
locat
observ
felin
chemotherapeut
agent
often
use
treat
felin
lymphoma
similar
use
dog
human
lymphoma
see
section
includ
doxorubicin
vincristin
cyclophosphamid
methotrex
lasparaginas
ccnu
prednison
gener
cat
toler
chemotherapi
quit
well
select
publish
protocol
treatment
felin
lymphoma
detail
tabl
current
combin
protocol
north
america
modif
chop
protocol
initi
design
human
oncolog
use
europ
cop
ie
without
addit
doxorubicin
use
often
cat
lymphoma
one
compil
report
result
similar
chop
studi
rel
case
entri
report
limit
activ
doxorubicin
singl
agent
cat
lymphoma
howev
larger
studi
use
combin
protocol
consist
report
addit
doxorubicin
necessari
attain
durabl
respons
european
australian
studi
report
less
favor
doxorubicin
respons
patient
popul
consist
higher
proport
mediastin
form
siames
cat
popul
less
frequent
includ
north
american
report
protocol
author
use
practic
present
tabl
protocol
use
mani
cat
variou
form
lymphoma
well
toler
current
canin
lymphoma
protocol
see
section
discontinu
chemotherapi
week
suffici
data
exist
show
dog
short
maintenancefre
protocol
good
superior
longer
mainten
protocol
longterm
mainten
protocol
prove
superior
maintenancefre
protocol
dog
human
lymphoma
like
hold
true
cat
although
data
exist
document
time
evid
contrari
exist
recommend
discontinu
chemotherapi
week
cat
attain
complet
remiss
although
doxorubicin
appear
effect
agent
treat
cat
lymphoma
north
america
speci
gener
less
toler
doxorubicin
dog
signific
toxic
result
use
dog
dosag
mgm
given
intraven
everi
week
howev
lower
dosag
eg
mgm
mgkg
given
intraven
doxorubicin
use
without
signific
toxic
major
toxic
note
doxorubicin
anorexia
myelosuppress
renal
toxic
perivascular
leakag
occur
sever
tissu
damag
clinic
doxorubicininduc
cardiac
toxic
document
cat
inform
indic
cat
resist
myocardi
damag
renal
toxic
produc
experiment
rat
box
singl
tumor
extranod
region
lymph
node
involv
two
nodal
area
side
diaphragm
two
singl
extranod
tumor
without
region
lymph
node
involv
side
diaphragm
resect
primari
gastrointestin
tract
tumor
usual
ileocec
area
without
involv
associ
mesenter
node
rabbit
report
cat
experi
incid
signific
enough
renal
function
cat
monitor
close
ie
serial
creatinin
urin
specif
graviti
analysi
therapi
session
stealth
liposom
form
doxorubicin
shown
increas
likelihood
renal
toxic
therefor
limit
use
speci
small
number
cat
lymphoma
treat
singl
agent
ccnu
dosag
rang
mgm
given
oral
everi
week
although
activ
note
partial
respons
report
littl
known
treatment
solitari
region
node
head
neck
close
resembl
hodgkin
lymphoma
histolog
one
studi
describ
clinic
outcom
four
cat
condit
research
found
cours
diseas
prolong
surgic
excis
singl
affect
node
one
cat
show
recurr
month
surgeri
second
surgeri
perform
cat
second
recurr
note
month
excis
cat
granular
cell
lymphoma
globul
leukocyt
tumor
tend
respond
poorli
chemotherapi
although
durabl
respons
report
current
case
treat
aggress
chemotherapi
allow
assess
respons
therapi
diseas
distinct
form
intestin
lymphoma
cat
compos
small
matur
lymphocyt
refer
lymphocyt
lymphoma
syndrom
report
respond
well
oral
prednison
mgcatday
chlorambucil
mgm
given
daili
consecut
day
everi
week
complet
respons
rate
report
median
remiss
surviv
durat
month
respect
radiat
therapi
use
effect
treat
local
lymphoma
epidur
mediastin
nasal
lymphoma
total
dose
gy
usual
result
complet
remiss
one
studi
cat
local
lymphoma
treat
radiat
alon
chemotherapi
dose
gy
eight
cat
achiev
complet
remiss
median
remiss
durat
year
radiat
therapi
also
use
effect
treat
nasal
lymphoma
complet
respons
norm
median
remiss
durat
exceed
year
expect
felvneg
cat
diseas
confin
nasal
paranas
caviti
nasal
lymphoma
radiotherapi
appear
superior
chemotherapi
report
median
remiss
durat
day
littl
publish
treatment
cutan
lymphoma
mycosi
fungoid
cat
howev
report
complet
respons
ccnu
exist
cat
solitari
mass
treat
surgic
excis
although
clinic
stage
necessari
rule
possibl
intern
involv
combin
chemotherapi
consid
multipl
site
involv
diseas
local
small
region
radiat
therapi
usual
also
effect
mycosi
fungoid
may
treat
effect
dog
retinoid
isotretinoin
accutan
dosag
mgkg
given
oral
daili
etretin
tegison
dosag
mgkg
given
oral
daili
howev
provid
precis
treatment
recommend
wide
varieti
clinic
set
cat
lymphoma
difficult
current
recommend
treat
cat
lymphoma
use
chopbas
protocol
see
tabl
doxorubicin
alon
mgm
given
iv
everi
week
five
total
treatment
palli
prednison
therapi
offer
client
declin
aggress
therapi
nutrit
support
especi
import
particularli
cat
alimentari
lymphoma
feed
tube
may
need
place
cat
undergo
chemotherapi
alimentari
lymphoma
particularli
anorexia
factor
see
chapter
section
b
ultim
cat
lymphoma
success
treat
chemotherapi
relaps
diseas
often
repres
recrudesc
tumor
drugresist
form
first
recurr
reinduct
first
attempt
use
induct
protocol
success
initi
gener
likelihood
respons
length
respons
half
initi
therapi
howev
subset
anim
enjoy
longterm
reinduct
reinduct
fail
cat
respond
initi
induct
socal
rescu
agent
rescu
protocol
attempt
drug
drug
combin
typic
found
standard
chop
protocol
withheld
use
drugresist
case
number
rescu
protocol
report
veterinari
literatur
review
previous
common
rescu
protocol
advoc
cat
resist
relaps
includ
singl
agent
use
combin
use
mitoxantron
doxorubicin
doxorubicin
part
origin
induct
protocol
ccnu
mopp
gener
overal
rescu
respons
rate
report
respons
usual
durabl
median
respons
month
norm
small
subset
anim
enjoy
longer
rescu
durat
gener
cat
enjoy
respons
rate
high
remiss
surviv
durat
long
dog
lymphoma
complet
respons
rate
rang
combin
chemotherapi
overal
median
remiss
surviv
durat
approxim
month
respect
howev
signific
proport
cat
achiev
complet
respons
combin
chemotherapi
enjoy
durabl
overal
remiss
surviv
time
ie
year
longer
respons
rate
length
respons
vari
accord
presenc
absenc
sever
prognost
factor
wide
variat
frequenc
great
heterogen
anatom
form
lymphoma
cat
make
specif
prognost
difficult
dog
lymphoma
studi
lump
anatom
group
togeth
produc
remiss
surviv
data
individu
group
number
gener
small
appli
statist
analysi
meaning
power
said
factor
appear
strongli
associ
posit
prognosi
cat
complet
respons
therapi
figur
unfortun
determin
treatment
neg
felv
statu
figur
earli
clinic
stage
figur
anatom
locat
addit
doxorubicin
treatment
protocol
unlik
dog
immunoreact
establish
neg
prognost
factor
cat
earli
report
may
contradict
recent
studi
partli
declin
felvassoci
lymphoma
patient
report
earli
literatur
may
equat
recent
popul
studi
gener
felvneg
cat
achiev
complet
respons
chopbas
protocol
high
likelihood
longterm
surviv
proport
aliv
approxim
aliv
year
diagnosi
cat
alimentari
lymphoma
median
surviv
time
month
expect
chemotherapi
includ
doxorubicin
one
studi
cat
alimentari
lymphoma
treatment
protocol
includ
doxorubicin
median
surviv
time
day
mediastin
lymphoma
felvposit
young
cat
associ
poorest
prognosi
surviv
time
approxim
month
expect
chemotherapi
contrast
older
felvneg
siames
cat
mediastin
lymphoma
appear
experi
remiss
rate
approach
respons
tend
quit
durabl
overal
cat
nasal
lymphoma
best
prognosi
local
radiotherapi
chemotherapi
radiotherapi
avail
gener
result
excel
control
median
surviv
time
approach
year
howev
cat
nasal
lymphoma
concurr
felv
infect
much
shorter
surviv
durat
renal
lymphoma
associ
shorter
surviv
time
publish
median
rang
month
studi
mooney
colleagu
cat
primari
renal
lymphoma
treat
combin
chemotherapi
complet
respons
cr
note
cat
nine
partial
respons
median
surviv
time
month
cat
show
complet
respons
month
show
partial
respons
durat
respons
chemotherapi
correl
degre
renal
insuffici
except
cat
bun
higher
mgdl
extens
cn
occur
treat
cat
investig
revis
chemotherapi
protocol
includ
cytosin
arabinosid
penetr
blood
barrier
theoret
prevent
reduc
cn
metastasi
howev
definit
improv
modif
document
studi
report
result
treatment
cat
spinal
lymphoma
one
studi
four
cat
treat
chemotherapi
lasparaginas
vincristin
prednison
combin
spinal
radiat
n
surgic
cytoreduct
n
cat
euthan
month
although
one
cat
surviv
month
anoth
studi
nine
cat
treat
chemotherapi
vincristin
cyclophosphamid
prednison
three
cat
achiev
complet
respons
durat
week
three
achiev
partial
respons
durat
week
one
cat
treat
dorsal
decompress
laminectomi
chemotherapi
surviv
month
although
number
small
overal
prognosi
spinal
lymphoma
poor
section
c
chapter
present
complet
discuss
leukemia
mpd
includ
gener
discuss
hematopoiesi
etiolog
lineag
classif
descript
classif
leukemia
cat
difficult
similar
clinic
patholog
featur
transit
overlap
mixtur
cell
type
involv
leukemia
neoplast
prolifer
hematopoiet
cell
origin
bone
marrow
cell
lineag
includ
myeloid
cell
neutrophil
basophil
eosinophil
monocyt
lymphoid
cell
megakaryocyt
erythrocyt
box
present
classif
scheme
leukemia
identifi
cat
leukemia
also
must
classifi
accord
degre
differenti
welldifferenti
leukemia
refer
chronic
leukemia
poorli
differenti
leukemia
usual
call
acut
leukemia
distinct
import
therapeut
manag
prognosi
leukemia
cat
acut
leukemia
usual
show
sign
sever
anemia
pale
mucou
membran
splenomegali
febril
episod
cat
chronic
leukemia
may
longer
durat
sign
mild
anemia
without
splenomegali
cat
suspect
leukemia
bone
marrow
aspir
biopsi
usual
diagnost
prefer
site
bone
marrow
aspir
proxim
humeru
iliac
crest
cat
acut
leukemia
like
malign
cellular
infiltr
organ
bone
marrow
bone
marrow
aspir
must
contain
abnorm
blast
cell
support
diagnosi
acut
leukemia
cat
suspect
cll
infiltr
bone
marrow
matur
lymphocyt
help
confirm
diagnosi
cat
leukemia
test
felv
fiv
determin
lineag
leukemia
challeng
distinguish
one
anoth
histolog
appear
histochem
stain
immunohistochem
analysi
cell
surfac
antigen
flow
cytometr
analysi
leukem
cell
cellular
antigen
identifi
lineag
addit
examin
blast
cell
electron
microscopi
may
reveal
characterist
ultrastructur
featur
frenchamericanbritish
fab
classif
system
box
consid
use
cat
myelodysplast
syndrom
almost
patient
felv
antigenem
lymphoid
leukemia
common
leukemia
cat
approxim
cat
lymphoma
also
leukem
blood
profil
common
lymphoid
leukemia
character
presenc
poorli
differenti
lymphoblast
prolymphocyt
blood
bone
marrow
cat
normal
low
wbc
count
cat
leucocytosi
circul
blast
moder
mark
anemia
common
bone
marrow
aspir
usual
reveal
extens
infiltr
lymphoblast
approxim
cat
felv
posit
malign
cell
tcell
phenotyp
cll
rare
report
cat
character
presenc
welldifferenti
small
matur
lymphocyt
peripher
blood
bone
marrow
although
cell
tcell
lineag
particularli
helper
bcell
cll
report
cat
cll
elev
wbc
count
ie
felv
neg
total
leukocyt
count
vari
may
rang
leukopenia
mark
leukocytosi
chronic
granulocyt
leukemia
gl
must
distinguish
leukemoid
reaction
associ
infect
acut
gl
character
larg
percentag
myeloblast
andor
progranulocyt
blood
bone
marrow
myeloblast
difficult
distinguish
lymphoblast
former
finer
chromatin
pattern
smaller
nucleustocytoplasm
ratio
promin
multipl
nucleoli
sometim
cytoplasm
granul
uncommon
cat
gl
recogniz
neoplast
cell
peripher
blood
bone
marrow
hypercellular
result
granulocyt
leukemia
cell
myelomonocyt
leukemia
mml
result
malign
transform
neutrophil
monocyt
form
leukemia
one
common
form
report
monocyt
leukemia
ml
rare
report
leukemia
gener
consid
acut
leukemia
regardless
morpholog
appear
cell
eosinophil
leukemia
el
rare
diagnos
cat
consid
variant
chronic
granulocyt
myeloid
leukemia
felv
induc
el
experiment
matur
eosinophil
outnumb
immatur
stage
anemia
uncommon
cat
associ
el
cat
usual
eosinophil
count
higher
without
immatur
cell
peripher
blood
bone
marrow
show
hyperplasia
eosinophil
precursor
myeloid
erythroid
ratio
e
significantli
increas
organ
infiltr
lymph
node
spleen
liver
seen
establish
diagnosi
el
import
rule
eosinophil
enter
parasit
eosinophil
granuloma
complex
allerg
disord
diagnos
el
difficult
hypereosinophil
syndrom
he
seen
diseas
condit
cat
he
character
mark
increas
eosinophil
count
bone
marrow
hyperplasia
eosinophil
precursor
multipl
organ
infiltr
matur
eosinophil
cat
sign
relat
gi
involv
basophil
leukemia
bl
consid
variant
chronic
granulocyt
leukemia
one
confirm
case
basophil
leukemia
report
cat
import
differenti
bl
system
mastocytosi
mast
cell
leukemia
mast
cell
numer
cytoplasm
granul
round
nuclei
basophil
segment
nuclei
cytoplasm
granul
superimpos
nucleu
give
motheaten
appear
erythrem
myelosi
erythrem
myelosi
em
mpd
character
excess
prolifer
erythroid
element
result
increas
nucleat
erythrocyt
rubriblast
metarubricyt
sever
anemia
common
peripher
blood
show
numer
nucleat
erythrocyt
moder
mark
anisocytosi
increas
erythrocyt
mean
cell
volum
bone
marrow
contain
preponder
normalappear
erythrocyt
precursor
cat
undergo
blast
transform
myeloblast
granulocyt
poorli
differenti
leukemia
previous
call
reticuloendotheliosi
transit
erythrem
myelosi
erythroleukemia
acut
granulocyt
leukemia
well
recogn
human
erythroleukemia
acut
erythrem
myelosi
develop
blast
transform
erythrem
myelosi
primit
erythroid
precursor
blood
bone
marrow
predomin
primit
cell
resembl
myeloblast
often
present
low
number
primari
erythrocytosi
rare
report
cat
diagnosi
base
elev
pcv
low
normal
serum
erythropoietin
activ
clinic
sign
associ
increas
red
blood
cell
rbc
volum
increas
blood
volum
viscos
caus
impair
blood
flow
stasi
tissu
hypoxia
neurolog
sign
seizur
blind
mental
depress
common
oral
mucou
membran
may
appear
brick
red
import
differenti
condit
secondari
polycythemia
caus
renal
tumor
chronic
hypoxia
righttoleft
cardiac
shunt
megakaryocyt
leukemia
character
abnorm
megakaryocyt
hyperplasia
bone
marrow
megakaryocyt
morpholog
abnorm
small
dwarf
megakaryocyt
nuclear
lobul
thrombocytopenia
thrombocytosi
may
present
human
form
leukemia
often
associ
extens
marrow
fibrosi
increas
reticulum
collagen
primari
thrombocythemia
rare
chronic
mpd
character
prolifer
megakaryocyt
elev
platelet
count
exceed
million
giant
platelet
platelet
abnorm
morpholog
may
seen
peripher
blood
one
case
report
cat
malign
histiocytosi
rare
condit
cat
character
system
prolifer
malign
macrophag
histiocyt
precursor
distinguish
characterist
diseas
erythrophagocytosi
hepatosplenomegali
progress
anemia
sometim
coomb
posit
thrombocytopenia
characterist
erythrophagocytosi
may
confus
possibl
immunemedi
anemia
bone
marrow
biopsi
rather
aspir
splenic
biopsi
may
necessari
establish
diagnosi
special
stain
use
acid
phosphatas
nonspecif
esteras
fluorid
inhibit
naphthol
butyr
substrat
may
necessari
indic
macrophag
origin
metaplasia
myelofibrosi
myeloid
hyperplasia
character
abnorm
growth
differenti
erythroid
myeloid
megakaryocyt
cell
type
vari
prolifer
fibroblast
marrow
anemia
leukopenia
thrombocytopenia
vari
combin
common
myelofibrosi
diagnos
felvposit
cat
directli
associ
viru
rather
consequ
myeloprolif
disord
myeloid
metaplasia
may
termin
acut
leukemia
therefor
may
consid
preleukem
event
use
chemotherapi
treat
disappoint
complet
respons
rate
report
cop
regimen
cat
treat
cop
four
achiev
cr
cat
partial
respons
median
remiss
month
rang
month
one
report
describ
shortterm
remiss
cat
lymphoid
leukemia
treat
low
dose
cytosin
arabinosid
mgm
given
subcutan
twice
daili
cll
treat
chlorambucil
mgkg
given
oral
mgcat
given
everi
day
prednison
dose
mgkg
given
oral
daili
cat
cll
better
prognosi
surviv
year
treat
chlorambucil
human
dog
treatment
withheld
patient
signific
clinic
sign
profound
cytopenia
one
studi
cat
cll
remain
stabl
without
chemotherapi
year
prognos
acut
nonlymphoblast
leukemia
gener
poor
although
except
exist
treatment
regimen
consist
combin
cytosin
arabinosid
cyclophosphamid
multipl
blood
transfus
effect
induc
respons
month
cat
acut
megakaryocyt
leukemia
hydroxyurea
hydrea
use
treat
chronic
myeloid
leukemia
primari
erythrocytosi
cat
primari
erythrocytosi
go
untreat
report
surviv
week
phlebotomi
alon
everi
month
use
treat
one
cat
surviv
longer
month
hydroxyurea
treatment
primari
erythrocytosi
use
eight
cat
surviv
longer
year
hydroxyurea
avail
mg
capsul
dosag
mgkg
given
oral
daili
cat
given
mg
everi
day
methemoglobulinemia
hemolyt
anemia
heinz
bodi
seen
better
recommend
drug
formul
mg
capsul
appropri
dosag
howev
care
must
use
make
capsul
hydroxyurea
potenti
carcinogen
recommend
treatment
schedul
hydroxyurea
mg
daili
everi
day
depend
type
leukemia
treatment
drug
toler
well
dosag
case
acut
ml
cat
undergo
treatment
cytarabin
doxorubicin
vincristin
prednisolon
report
partial
remiss
note
approxim
month
cat
surviv
month
diagnosi
retrospect
studi
subcommitte
reexamin
criteria
classif
system
spearhead
larg
multiinstitut
studi
valid
criteria
mpd
uncommon
rare
dog
occur
time
less
frequent
lymphoprolif
disord
accur
inform
incid
epidemiolog
inform
await
consist
use
uniform
classif
system
see
later
discuss
known
age
breed
gender
predisposit
exist
although
larg
breed
dog
overrepres
retrospect
studi
dog
etiolog
spontan
occur
leukemia
unknown
genet
environment
factor
includ
exposur
radiat
drug
toxic
chemic
probabl
play
role
human
acquir
chromosom
derang
lead
clonal
overgrowth
arrest
develop
chromosom
abnorm
report
dog
acut
myeloid
leukemia
aml
chronic
myelogen
leukemia
cml
lymphoid
leukemia
howev
karyotyp
difficult
perform
dog
owe
larg
number
morpholog
similar
chromosom
resist
band
definit
genet
factor
canin
mpd
await
applic
molecular
techniqu
use
canin
genom
map
certain
form
leukemia
dog
produc
experiment
irradi
contrast
mpd
cat
caus
viral
agent
demonstr
dog
although
retroviruslik
bud
particl
observ
neoplast
cell
dog
granulocyt
leukemia
review
normal
hematopoiesi
aid
clinician
understand
variou
manifest
mpd
hematopoiesi
process
prolifer
differenti
matur
stem
cell
termin
differenti
blood
cell
simplifi
schemat
present
figur
pluripot
stem
cell
differenti
either
lymphopoiet
hematopoiet
multipot
stem
cell
influenc
specif
regulatori
microenvironment
factor
multipot
stem
cell
bone
marrow
differenti
progenitor
cell
commit
specif
hematopoiet
cell
line
erythroid
granulocyticmonocyt
megakaryocyt
cell
matur
result
product
termin
differenti
blood
cellserythrocyt
granulocyt
monocyt
plateletsthat
deliv
circul
case
matur
reticulocyt
erythrocyt
final
develop
may
occur
spleen
prolifer
differenti
hematopoiet
cell
control
group
regulatori
growth
factor
erythropoietin
best
character
regul
erythroid
prolifer
differenti
produc
kidney
chang
oxygen
tension
detect
myeloid
compart
depend
group
factor
collect
refer
colonystimul
factor
csf
factor
act
level
commit
progenitor
cell
also
influenc
function
capabl
matur
cell
factor
broad
spectrum
activ
other
restrict
target
cell
action
csf
produc
vitro
multitud
cell
type
includ
monocyt
macrophag
lymphocyt
endotheli
cell
cell
like
play
role
product
regul
factor
vivo
gene
thrombopoietin
also
clone
hormon
alon
appar
induc
differenti
megakaryocyt
platelet
product
recombin
form
mani
hormon
becom
increasingli
avail
clonal
disord
bone
marrow
includ
myeloaplasia
usual
refer
aplast
anemia
myelodysplasia
myeloprolifer
preleukem
syndrom
character
peripher
pancytopenia
bone
marrow
hyperplasia
matur
arrest
correctli
call
myelodysplasia
syndrom
alway
progress
overt
leukemia
syndrom
describ
cat
usual
associ
felv
infect
rare
recogn
dog
mpd
may
manifest
abnorm
differ
cell
line
hematopoiet
cell
share
common
stem
cell
addit
transform
one
mpd
anoth
may
occur
mpd
classifi
sever
way
term
acut
chronic
refer
degre
cellular
differenti
leukem
cell
term
also
correl
biolog
behavior
neoplasm
disord
result
uncontrol
prolifer
cell
incap
matur
lead
accumul
poorli
differenti
blast
cell
disord
call
acut
mpd
acut
nonlymphocyt
leukemia
includ
umbrella
term
acut
myeloid
leukemia
disord
result
unregul
prolifer
cell
exhibit
progress
albeit
incomplet
defect
matur
lead
accumul
differenti
cell
disord
call
chronic
mpd
includ
polycythemia
vera
cml
variant
essenti
thrombocythemia
possibl
primari
myelofibrosi
mpd
classifi
lineag
domin
cell
type
type
defin
romanowski
stain
special
cytochem
stain
ultrastructur
featur
immunolog
cell
marker
recent
classifi
subtyp
see
later
discuss
acut
leukemia
sudden
onset
aggress
acut
chronic
disord
howev
abnorm
prolifer
matur
function
characterist
occur
hematopoiet
cell
line
addit
normal
hematopoiesi
advers
affect
anim
leukemia
usual
decreas
number
circul
normal
cell
pathogenesi
cytopenia
complex
may
result
part
product
inhibitori
factor
eventu
neoplast
cell
displac
normal
hematopoiet
cell
process
call
myelophthisi
anemia
thrombocytopenia
particularli
common
neutropenia
thrombocytopenia
result
infect
hemorrhag
may
deleteri
anim
primari
diseas
process
despit
dissemin
natur
diseas
time
diagnosi
parenchym
organ
dysfunct
usual
occur
advanc
case
mpd
aml
rare
character
aberr
prolifer
clone
cell
without
matur
result
accumul
immatur
blast
cell
bone
marrow
peripher
blood
figur
wbc
count
vari
rang
leukopenia
count
greater
spleen
liver
lymph
node
commonli
involv
tissu
may
infiltr
well
includ
tonsil
kidney
heart
cn
characterist
age
note
even
young
dog
may
affect
clinic
cours
disord
tend
rapid
product
normal
peripher
blood
cell
usual
diminish
absent
anemia
neutropenia
thrombocytopenia
common
infect
hemorrhag
common
sequela
occasion
malign
blast
present
bone
marrow
peripher
blood
call
aleukem
leukemia
subleukem
leukemia
suggest
normal
decreas
wbc
neoplast
cell
circul
anim
leukemia
studi
group
form
auspic
american
societi
veterinari
clinic
patholog
develop
specif
morpholog
cytochem
criteria
classifi
acut
nonlymphocyt
leukemia
dog
cat
recognit
specif
subtyp
leukemia
necessari
accumul
accur
use
inform
prognosi
respons
treatment
comparison
studi
differ
site
group
propos
classif
system
follow
adapt
frenchamericanbritish
fab
system
criteria
establish
nation
cancer
institut
workshop
group
member
examin
blood
bone
marrow
dog
cat
mpd
romanowskystain
specimen
examin
first
identifi
blast
cell
percentag
lineag
specif
determin
use
cytochem
marker
percentag
blast
inform
lineag
specif
use
combin
classifi
disord
acut
undifferenti
leukemia
aul
acut
myeloid
leukemia
aml
subtyp
erythroleukemia
without
erythroid
predomin
subtyp
see
box
except
acut
promyelocyt
leukemia
subtyp
subtyp
describ
dog
howev
modifi
fab
system
recent
adopt
name
given
disord
literatur
vari
consider
addit
absenc
special
cytochem
stain
immunophenotyp
andor
electron
microscopi
specif
subtyp
leukemia
often
uncertain
make
retrospect
analysi
epidemiolog
inform
prognosi
respons
therapi
confus
best
although
defin
specif
subtyp
may
seem
academ
exercis
owe
uniformli
poor
prognosi
acut
leukemia
inform
critic
improv
manag
diseas
low
incid
mpd
nation
intern
cooper
effort
requir
accumul
inform
pathogenesi
specif
subtyp
respons
differ
treatment
modal
use
uniform
classif
system
essenti
first
step
differ
form
aml
shown
figur
ae
frequent
report
form
aml
dog
acut
myeloblast
leukemia
acut
myelomonocyt
leukemia
megakaryoblast
leukemia
also
well
recogn
dog
may
associ
platelet
dysfunct
monocyt
leukemia
like
includ
without
monocyt
differenti
case
diagnosi
may
chronic
myelomonocyt
chronic
monocyt
leukemia
see
later
discuss
report
dog
spontan
occur
erythroleukemia
leukem
cell
compris
myeloblast
monoblast
erythroid
element
aul
uncertain
lineag
neg
cytochem
marker
leukemia
distinguish
lymphoid
leukemia
flow
cytometr
analysi
leukem
cell
cellular
antigen
identifi
lineag
addit
examin
blast
cell
electron
microscopi
may
reveal
characterist
ultrastructur
featur
chronic
mpd
character
excess
product
differenti
bone
marrow
cell
result
accumul
erythrocyt
polycythemia
vera
granulocyt
andor
monocyt
chronic
myelogen
leukemia
variant
platelet
essenti
thrombocythemia
primari
myelofibrosi
clonal
disord
marrow
stromal
cell
character
prolifer
fibroblast
accumul
collagen
bone
marrow
recogn
anim
myelofibrosi
consid
respons
injuri
may
occur
secondari
mpd
polycythemia
vera
pv
clonal
disord
stem
cell
although
whether
defect
pluripot
stem
cell
hematopoiet
multipot
stem
cell
still
unclear
human
progenitor
cell
increas
sensit
insulinlik
growth
factor
stimul
hematopoiesi
whether
hypersensit
primari
defect
occur
secondari
anoth
gene
mutat
unknown
case
result
overproduct
rbc
diseas
rare
must
distinguish
common
caus
polycythemia
includ
rel
secondari
absolut
polycythemia
see
later
discuss
pv
neoplast
prolifer
erythroid
seri
termin
differenti
rbc
occur
diseas
report
mostli
middleag
dog
breed
gender
predilect
note
pv
character
increas
rbc
mass
evidenc
elev
pcv
rbc
count
hemoglobin
concentr
pcv
typic
rang
bone
marrow
hyperplast
although
e
tend
normal
contrast
diseas
human
cell
line
appear
involv
transform
mpd
report
diseas
dog
may
appropri
call
primari
erythrocytosi
cml
neoplast
prolifer
neutrophil
seri
although
concurr
eosinophil
basophil
differenti
occur
cml
occur
dog
age
neutrophil
neutrophil
precursor
accumul
bone
marrow
peripher
blood
invad
organ
peripher
wbc
count
usual
alway
higher
immatur
matur
neutrophil
present
see
figur
f
matur
form
usual
numer
sometim
uneven
left
shift
present
sign
dysplasia
may
evid
includ
hypersegment
ring
nuclei
giant
form
eosinophil
basophil
may
also
increas
bone
marrow
character
granulocyt
hyperplasia
morpholog
abnorm
may
present
erythroid
megakaryocyt
line
may
affect
result
anemia
thrombocytopenia
less
commonli
thrombocytosi
cml
must
distinguish
sever
neutrophil
leukocytosi
leukemoid
reaction
caus
inflamm
immunemedi
diseas
leukemoid
reaction
also
occur
paraneoplast
syndrom
human
cml
characterist
cytogenet
abnorm
present
bone
marrow
cell
signifi
lesion
level
earli
multipot
stem
cell
typic
individu
chromosom
transloc
result
philadelphia
chromosom
consist
cytogenet
abnorm
demonstr
spontan
occur
cml
dog
variant
cml
chronic
myelomonocyt
leukemia
cmml
chronic
monocyt
leukemia
cmol
diagnos
made
base
percentag
monocyt
leukem
cell
popul
besid
accumul
bone
marrow
peripher
blood
leukem
cell
invad
red
pulp
spleen
periport
sinusoid
area
liver
sometim
lymph
node
organ
eg
kidney
heart
lung
less
commonli
affect
addit
extramedullari
hematopoiesi
may
present
liver
spleen
death
usual
result
complic
infect
hemorrhag
secondari
neutrophil
dysfunct
thrombocytopenia
case
cml
may
termin
blast
crisi
transform
occur
predomin
welldifferenti
granulocyt
excess
number
poorli
differenti
blast
cell
peripher
blood
bone
marrow
phenomenon
well
document
dog
basophil
leukemia
although
rare
report
dog
character
elev
wbc
count
high
proport
basophil
peripher
blood
bone
marrow
hepatosplenomegali
lymphadenopathi
thrombocytosi
may
present
dog
anem
basophil
leukemia
distinguish
mast
cell
leukemia
mastocytosi
whether
dog
develop
eosinophil
leukemia
remain
question
report
case
high
blood
eosinophil
count
eosinophil
infiltr
organ
one
dog
respond
well
treatment
corticosteroid
distinct
neoplast
prolifer
eosinophil
idiopath
hypereosinophil
syndrom
remain
elus
disord
associ
eosinophilia
eg
parasit
skin
diseas
diseas
respiratori
gi
tract
consid
first
anim
eosinophilia
one
distinguish
featur
clonal
reactiv
eosinophilia
compris
polyclon
cell
neoplast
condit
aris
singl
clone
clonal
assay
becom
avail
discrep
may
resolv
human
essenti
thrombocythemia
primari
thrombocytosi
character
platelet
count
persist
higher
blast
cell
circul
mark
megakaryocyt
hyperplasia
bone
marrow
without
myelofibrosi
present
thrombosi
bleed
common
sequela
patient
splenomegali
mpd
especi
pv
rule
patient
primari
disord
associ
reactiv
thrombocytosi
inflamm
hemolyt
anemia
iron
defici
anemia
malign
recoveri
sever
hemorrhag
rebound
immunemedi
thrombocytopenia
abscenc
spleen
addit
certain
drug
vincristin
induc
thrombocytosi
essenti
thrombocythemia
recogn
dog
one
dog
platelet
count
exceed
millionml
bizarr
giant
form
abnorm
granul
present
bone
marrow
contain
increas
number
megakaryocyt
megakaryoblast
circul
blast
cell
seen
find
includ
splenomegali
gi
bleed
increas
number
circul
basophil
caus
secondari
reactiv
thrombocytosi
rule
basophilia
also
report
recent
case
anoth
dog
primari
thrombocytosi
diagnos
progress
cml
case
report
literatur
essenti
thrombocythemia
dog
microcyt
hypochrom
anemia
iron
defici
anemia
associ
reactiv
secondari
thrombocytosi
care
must
taken
rule
disord
howev
spuriou
microcytosi
may
report
dog
mani
giant
platelet
count
analyz
small
rbc
microscop
review
blood
film
may
help
case
primari
myelofibrosi
clonal
prolifer
marrow
fibroblast
report
dog
human
myelofibrosi
character
collagen
deposit
bone
marrow
increas
number
megakaryocyt
mani
morpholog
abnorm
fact
breakdown
intramedullari
megakaryocyt
subsequ
releas
factor
promot
fibroblast
prolifer
inhibit
collagen
breakdown
may
underli
pathogenesi
fibrosi
focal
osteosclerosi
sometim
present
anemia
thrombocytopenia
splenomegali
myeloid
metaplasia
product
hematopoiet
cell
outsid
bone
marrow
consist
featur
extramedullari
hematopoiesi
ineffect
maintain
restor
normal
peripher
blood
count
dog
myelofibrosi
occur
secondari
mpd
radiat
damag
congenit
hemolyt
anemia
case
incit
caus
unknown
idiopath
myelofibrosi
concurr
marrow
necrosi
may
occur
case
ehrlichiosi
septicemia
drug
toxic
estrogen
cephalosporin
specul
fibroblast
prolifer
respons
releas
inflammatori
mediat
associ
necrosi
myeloid
metaplasia
report
occur
liver
spleen
lung
extramedullari
hematopoiesi
ineffect
prevent
correct
pancytopenia
eventu
develop
dysfunct
hematopoiet
system
manifest
varieti
abnorm
compris
myelodysplast
syndrom
md
dog
syndrom
rare
cytopenia
usual
seen
two
three
line
peripher
blood
anemia
neutropenia
andor
thrombocytopenia
blood
abnorm
includ
macrocyt
erythrocyt
metarubricytosi
bone
marrow
typic
normocellular
hypercellular
dysplast
chang
evid
sever
cell
line
blast
cell
present
account
fewer
nucleat
cell
although
threshold
may
alter
fewer
myelodysplasia
sometim
call
preleukemia
case
may
progress
acut
leukemia
human
cat
md
clonal
disord
consid
neoplast
dog
mpd
similar
present
regardless
specif
diseas
entiti
although
anim
acut
mpd
acut
onset
ill
rapid
clinic
cours
histori
lethargi
inappet
weight
loss
common
clinic
sign
includ
emaci
persist
fever
pallor
petechi
hepatosplenomegali
less
commonli
lymphadenopathi
enlarg
tonsil
shift
leg
lame
ocular
lesion
recurr
infect
also
seen
vomit
diarrhea
dyspnea
neurolog
sign
variabl
featur
serum
chemistri
may
within
refer
interv
chang
signific
organ
infiltr
occur
anim
msd
may
letharg
anorect
may
pallor
fever
hepatosplenomegali
pv
dog
often
erythema
mucou
membran
increas
rbc
mass
dog
polydips
addit
neurolog
sign
may
present
disorient
ataxia
seizur
thought
result
hyperviscos
hypervolemia
hepatosplenomegali
usual
absent
peripher
blood
abnorm
consist
found
addit
presenc
neoplast
cell
abnorm
may
present
includ
decreas
number
normal
cell
hematopoiet
cell
line
occasion
nucleat
rbc
present
blood
half
dog
acut
nonlymphocyt
leukemia
nonregen
anemia
thrombocytopenia
present
case
anemia
usual
normocyt
normochrom
although
macrocyt
anemia
sometim
present
pathogen
mechan
includ
effect
inhibitori
factor
lead
ineffect
hematopoiesi
myelophthisi
immunemedi
anemia
secondari
neoplasia
hemorrhag
secondari
thrombocytopenia
platelet
dysfunct
dic
anemia
sever
acut
mpd
although
anemia
thrombocytopenia
may
milder
anim
subtyp
acut
monocyt
leukemia
myelofibrosi
anemia
character
anisocytosi
poikilocytosi
addit
pancytopenia
leukoerythroblastosi
immatur
erythroid
myeloid
cell
circul
may
present
phenomena
probabl
result
replac
marrow
fibrou
tissu
result
shear
red
cell
escap
immatur
cell
normal
confin
bone
marrow
pv
pcv
elev
usual
rang
bone
marrow
hyperplast
e
usual
normal
rang
neoplast
cell
often
defect
function
platelet
dysfunct
report
dog
acut
megakaryoblast
leukemia
cml
neutrophil
decreas
phagocyt
capac
abnorm
one
except
report
cml
dog
neutrophil
enhanc
phagocyt
capac
superoxid
product
author
hypothes
increas
synthesi
granulocytemacrophag
colonystimul
factor
gmcsf
result
lactoferrin
defici
neoplast
neutrophil
mediat
enhanc
function
cell
case
mpd
diagnosi
depend
examin
peripher
blood
bone
marrow
acut
mpd
diagnos
basi
find
blast
cell
clearli
visibl
nucleoli
blood
bone
marrow
dog
acut
leukemia
circul
blast
cell
may
present
low
number
peripher
blood
smear
search
care
especi
feather
edg
even
blast
detect
circul
indic
bone
marrow
diseas
nonregen
anemia
thrombocytopenia
usual
present
occasion
neoplast
cell
found
csf
anim
invas
cn
smear
aspir
tissu
lymph
node
spleen
liver
may
contain
blast
usual
contribut
littl
diagnost
workup
examin
blast
stain
standard
romanowski
stain
may
give
clue
lineag
cell
see
figur
c
e
aml
addit
myeloblast
progranulocyt
characterist
azurophil
granul
may
present
myelomonocyt
leukemia
nuclei
blast
usual
pleomorph
round
lobul
form
cell
cytoplasm
may
contain
larg
azurophil
granul
vacuol
blast
megakaryocyt
leukemia
may
contain
vacuol
may
cytoplasm
bleb
addit
bizarr
macroplatelet
may
present
although
distinguish
morpholog
featur
may
suggest
definit
diagnosi
cytochem
stain
immunophenotyp
usual
requir
defin
lineag
blast
sever
investig
report
modif
diagnos
cytochem
stain
especi
import
distinguish
aml
lymphocyt
leukemia
provid
prognost
inform
owner
anim
leukemia
group
recommend
follow
diagnost
criteria
figur
use
wellprepar
romanowskystain
blood
bone
marrow
film
minimum
cell
count
determin
leukocyt
differenti
blood
percentag
blast
cell
bone
marrow
blood
bone
marrow
blast
cell
calcul
percentag
nucleat
cell
anc
nonerythroid
cell
nec
character
use
cytochem
marker
neutrophil
differenti
identifi
posit
stain
blast
peroxidas
sudan
black
b
chloracet
esteras
nonspecif
esteras
alphanaphthyl
acet
esteras
alphanaphthyl
butyr
esteras
especi
inhibit
sodium
fluorid
mark
monocyt
canin
monocyt
may
also
contain
peroxidaseposit
granul
acetylcholinesteras
marker
megakaryocyt
dog
cat
addit
posit
immunostain
von
willebrand
factor
factor
viiirel
antigen
platelet
glycoprotein
surfac
blast
identifi
megakaryocyt
precursor
alkalin
phosphatas
ap
rare
mark
normal
cell
dog
cat
present
blast
cell
acut
myeloblast
myelomonocyt
leukemia
howev
report
ap
activ
lymphoid
leukemia
dog
specif
marker
myeloid
cell
certain
omegaexonucleas
specif
marker
basophil
also
posit
chloracet
esteras
activ
blood
bone
marrow
differenti
count
cytochem
stain
perform
interpret
experienc
veterinari
cytopathologist
erythroid
cell
compris
less
anc
blast
cell
account
diagnosi
aml
aul
made
erythroid
cell
anc
blast
cell
diagnosi
erythroleukemia
made
rubriblast
compris
signific
proport
blast
cell
diagnosi
erythroleukemia
erythroid
predomin
made
note
human
aml
classif
system
blast
threshold
lower
case
electron
microscopi
requir
identifi
lineag
blast
cell
exampl
megakaryocyt
precursor
posit
platelet
peroxidas
activ
contain
demarc
membran
alpha
granul
featur
detect
ultrastructur
level
immunophenotyp
use
identifi
cell
lineag
human
patient
await
develop
appropri
marker
anim
speci
see
later
discuss
hematopoiet
cell
human
leukemia
often
abnorm
chromosom
pattern
cytogenet
abnorm
found
leukem
cell
small
number
dog
clear
whether
chromosom
aberr
primari
caus
secondari
caus
leukemia
consist
karyotyp
pattern
identifi
correl
leukem
subtyp
cytogenet
analysi
eventu
may
yield
import
diagnost
prognost
inform
becom
valuabl
tool
evalu
remiss
predict
relaps
although
morpholog
cytochem
analys
form
mainstay
cell
identif
newer
technolog
use
routin
classifi
leukemia
use
monoclon
antibodi
detect
antigen
associ
certain
cell
type
cell
immunophenotyp
use
flow
cytometr
analysi
immunocytochemistri
lymphoid
nonlymphoid
acut
leukemia
posit
mani
lymphocyt
marker
includ
bone
marrow
erythroid
cell
igg
avail
dog
use
rule
lymphoblast
leukemia
dog
acut
leukemia
marker
includ
myeloperoxidas
mpo
myeloid
cell
megakaryoblast
overlap
express
cell
antigen
occur
exampl
canin
human
granulocyt
express
best
use
panel
antibodi
similar
use
batteri
cytochem
stain
antigen
often
express
multipl
lineag
lineag
infidel
occur
test
becom
valuabl
avail
canin
reagent
current
myeloid
neoplasm
subcommitte
acvp
oncolog
committe
recommend
follow
immunophenotyp
panel
done
bone
marrow
andor
blood
smear
character
anim
leukemia
b
lymphocyt
lymphocyt
myeloid
cell
mpo
megakaryoblast
dendrit
cell
acut
leukemia
owe
degre
differenti
cell
chronic
mpd
disord
must
distinguish
nonneoplast
caus
increas
cell
type
allow
diagnosi
pv
test
first
must
establish
polycythemia
absolut
rather
rel
rel
polycythemia
plasma
volum
decreas
hemoconcentr
dehydr
hypovolemia
absolut
red
cell
mass
increas
splenic
contract
also
result
rel
polycythemia
absolut
polycythemia
rbc
mass
increas
usual
occur
secondari
tissu
hypoxia
caus
appropri
increas
product
erythropoietin
rare
case
erythropoietin
may
produc
inappropri
tumor
eg
renal
cell
carcinoma
renal
diseas
pyelonephr
local
renal
hypoxia
caus
polycythemia
elimin
appropri
laboratori
work
thorac
radiograph
arteri
blood
ga
analysi
renal
ultrasonographi
human
pv
plasma
erythropoietin
epo
level
low
epo
level
dog
pv
tend
low
lownorm
wherea
anim
secondari
absolut
polycythemia
level
high
sampl
determin
epo
concentr
taken
therapeut
phlebotomi
treat
hyperviscos
owe
fluctuat
epo
level
repeat
result
incongru
inform
cml
dog
pathognomon
featur
common
caus
mark
leukocytosi
left
shift
leukemoid
reaction
granulocyt
hyperplasia
bone
marrow
must
elimin
includ
infect
especi
pyogen
one
immunemedi
diseas
malign
neoplasm
cml
matur
sometim
appear
disorderli
variat
size
shape
neutrophil
may
occur
level
matur
addit
neoplast
leukocyt
may
disintegr
rapidli
appear
vacuol
invas
natur
cml
biopsi
liver
spleen
may
also
help
distinguish
true
leukemia
leukemoid
reaction
assum
anim
toler
procedur
characterist
cytogenet
abnorm
found
dog
cml
analysi
may
help
basophil
leukemia
diagnos
find
excess
number
basophil
circul
bone
marrow
basophil
leukemia
must
differenti
mastocytosi
base
morpholog
cell
type
present
basophil
segment
nucleu
variabl
size
granul
wherea
mast
cell
round
oval
nucleu
may
partli
total
obscur
small
round
metachromaticstain
granul
distinct
usual
easi
make
howev
basophil
leukemia
chang
morpholog
nucleu
granul
make
distinct
less
clear
essenti
thrombocythemia
diagnos
base
find
persist
excess
thrombocytosi
without
circul
blast
cell
absenc
anoth
mpd
eg
polycythemia
vera
myelofibrosi
disord
known
caus
secondari
thrombocytosi
includ
iron
defici
anemia
chronic
inflammatori
diseas
recoveri
sever
hemorrhag
rebound
immunemedi
thrombocytopenia
absenc
spleen
thrombocytosi
transient
disord
abat
resolut
primari
diseas
essenti
thrombocythemia
platelet
morpholog
may
abnorm
bizarr
giant
form
abnorm
granul
bone
marrow
megakaryocyt
hyperplasia
consist
featur
dysplast
chang
may
evid
megakaryocyt
spuriou
hyperkalemia
may
present
serum
sampl
dog
thrombocytosi
caus
releas
potassium
platelet
clot
format
measur
potassium
plasma
recommend
case
usual
demonstr
potassium
concentr
within
refer
interv
platelet
aggreg
variabl
report
impair
enhanc
one
dog
measur
plasma
thrombopoietin
tpo
concentr
normal
whether
tpo
play
role
essenti
thrombocythemia
suppress
high
platelet
mass
unclear
elucid
pathogenesi
disord
aid
recent
clone
gene
thrombopoietin
receptor
protooncogen
mpl
md
abnorm
two
three
cell
line
usual
manifest
peripher
blood
neutropenia
without
left
shift
nonregen
anemia
thrombocytopenia
chang
includ
macrocytosi
metarubricytosi
bone
marrow
typic
normocellular
hypercellular
increas
e
blast
cell
although
increas
account
fewer
nucleat
cell
blast
threshold
may
chang
fewer
report
dog
primari
secondari
md
one
dog
blast
cell
percentag
less
dysplast
chang
detect
cell
line
dyserythropoiesi
character
asynchron
matur
erythroid
cell
typifi
larg
hemoglobin
cell
immatur
nuclei
megaloblast
chang
erythroid
compon
domin
md
call
mdser
see
box
dysgranulopoiesi
giant
neutrophil
precursor
abnorm
nuclear
segment
cytoplasm
granul
seen
final
dysthrombopoiesi
character
giant
platelet
micromegakaryocyt
myelofibrosi
suspect
anim
nonregen
anemia
pancytopenia
abnorm
erythrocyt
morpholog
especi
shape
leukoerythroblastosi
bone
marrow
aspir
usual
unsuccess
result
dri
tap
necessit
bone
marrow
biopsi
taken
jamshidi
needl
specimen
process
routin
histopatholog
examin
necessari
special
stain
fibrou
tissu
use
myelofibrosi
occur
secondari
diseas
bone
marrow
eg
mpd
chronic
hemolyt
anemia
bone
marrow
necrosi
clinician
look
primari
diseas
process
poor
respons
acut
nonlymphocyt
leukemia
treatment
unreward
date
howev
littl
inform
avail
respons
specif
subtyp
leukemia
uniform
chemotherapeut
protocol
partli
rariti
diseas
process
pauciti
case
literatur
clinician
advis
contact
veterinari
oncologist
advic
new
protocol
appropri
manag
case
therapeut
goal
erad
leukem
cell
reestablish
normal
hematopoiesi
current
best
accomplish
cytoreduct
chemotherapi
agent
commonli
use
includ
combin
cytosin
arabinosid
anthracyclin
eg
doxorubicin
cyclophosphamid
vincristin
prednison
human
introduct
cytosin
arabinosid
singl
import
develop
therapi
acut
nonlymphocyt
leukemia
dog
regimen
mgm
cytosin
arabinosid
given
slow
infus
hour
daili
day
repeat
weekli
use
doxorubicin
mgm
given
intraven
everi
week
administ
interv
altern
cytosin
arabinosid
remiss
achiev
evidenc
normal
hemogram
coap
protocol
cyclophosphamid
vincristin
cytosin
arabinosid
prednison
describ
canin
lymphoma
could
use
mainten
therapi
anoth
protocol
use
treat
acut
myeloblast
leukemia
present
tabl
regardless
chemotherapi
protocol
use
signific
bone
marrow
suppress
develop
intens
support
care
necessari
transfus
whole
blood
plateletrich
plasma
may
requir
treat
anemia
thrombocytopenia
infect
manag
aggress
antibiot
therapi
gener
poor
respons
major
thrust
therapi
may
provid
palli
support
care
pv
therapi
direct
reduc
red
cell
mass
pcv
reduc
one
sixth
start
valu
phlebotomi
perform
need
administr
appropri
colloid
crystalloid
solut
replac
lost
electrolyt
ml
whole
blood
per
kilogram
bodi
weight
remov
regular
interv
human
phlebotomi
continu
therapeut
approach
use
frequent
radiophosphoru
p
shown
provid
longterm
control
use
special
center
chemotherapeut
drug
choic
hydroxyurea
inhibitor
dna
synthesi
drug
administ
initi
dosag
mgkg
day
dosag
reduc
mgkg
given
oral
daili
major
goal
treatment
maintain
pcv
close
normal
possibl
cml
best
manag
chemotherapi
control
prolifer
abnorm
cell
line
improv
qualiti
life
hydroxyurea
effect
agent
treat
cml
chronic
phase
initi
dosag
mgkg
given
twice
daili
treatment
hydroxyurea
continu
leukocyt
count
fall
cellsml
dosag
hydroxyurea
reduc
daili
basi
mgkg
given
biweeki
triweekli
human
alkyl
agent
busulfan
use
altern
effect
dosag
establish
dog
follow
human
protocol
mgkgday
given
oral
administ
leukocyt
count
reduc
cellsml
despit
respons
chemotherapi
control
mani
month
dog
cml
eventu
enter
termin
phase
diseas
one
studi
seven
dog
cml
four
underw
termin
phase
blast
crisi
human
blast
crisi
may
lymphoid
myeloid
dog
lineag
blast
cell
often
determin
dog
poor
prognosi
best
treatment
consid
would
list
tabl
case
report
one
dog
treat
success
combin
chemotherapi
protocol
includ
vincristin
cytosin
arabinosid
cyclophosphamid
prednison
treatment
controversi
human
lack
evid
asymptomat
patient
benefit
chemotherapi
patient
thrombosi
bleed
given
cytoreduct
therapi
hydroxyurea
drug
choic
initi
control
thrombocytosi
standard
therapeut
regimen
exist
md
often
human
receiv
treatment
cytopenia
caus
clinic
sign
transfus
given
necessari
patient
fever
evalu
aggress
detect
infect
growth
factor
erythropoietin
gmcsf
granulocyt
colonystimul
factor
gcsf
sometim
use
patient
requir
frequent
transfus
increas
blood
cell
count
enhanc
neutrophil
function
one
case
report
human
epo
ukg
given
subcutan
everi
hour
administ
dog
msd
profound
anemia
rational
erythropoietin
promot
termin
differenti
dysplast
erythrocyt
pcv
increas
day
epo
treatment
dog
remain
remiss
longer
month
factor
induc
differenti
hematopoiet
cell
includ
retino
acid
analog
dihydroxyvitamin
interferonalpha
convent
chemotherapeut
agent
cytosin
arabinosid
propens
factor
enhanc
progress
leukemia
known
mani
case
potenti
risk
exist
gener
prognosi
anim
chronic
mpd
better
dog
acut
mpd
prognosi
grave
prognosi
pv
chronic
myelogen
leukemia
guard
signific
remiss
achiev
certain
therapeut
regimen
care
monitor
anim
commonli
surviv
year
longer
develop
blast
crisi
portend
grave
prognosi
pathophysiolog
therapi
nonlymphocyt
leukemia
human
studi
intens
mpd
demonstr
clonal
abnorm
evid
hematopoiet
cell
line
leukemogenesi
like
caus
mutat
amplif
protooncogen
twostep
process
initi
involv
singl
cell
follow
addit
chromosom
alter
may
involv
oncogen
alter
manifest
chromosom
abnorm
environment
factor
known
caus
leukemia
exposur
highdos
radiat
benzen
chronic
exposur
alkyl
agent
new
classif
system
incorpor
genet
mutat
accur
reflect
prognos
facilit
use
consist
categor
among
institut
therapeut
modal
investig
develop
includ
combin
chemotherapi
immunotherapi
cytokin
therapi
drugresist
modul
proapoptot
agent
antiangiogen
factor
signal
transductionact
agent
bone
marrow
transplant
prognosi
chronic
mpd
better
acut
mpd
acut
nonlymphocyt
leukemia
prognosi
better
children
adult
adult
receiv
chemotherapi
maintain
remiss
longer
year
spontan
canin
diseas
probabl
occur
infrequ
serv
use
model
mpd
induc
experiment
dog
irradi
transplant
attempt
creat
model
studi
mani
similar
human
canin
mpd
exist
veterinari
medicin
may
benefit
therapeut
advanc
made
human
field
plasma
cell
neoplasm
aris
cell
blymphocyt
plasma
cell
lineag
prolifer
form
malign
popul
similar
cell
popul
believ
instanc
monoclon
ie
deriv
singl
cell
cell
typic
produc
homogen
immunoglobulin
although
exampl
biclon
polyclon
plasma
cell
neoplasm
exist
wide
varieti
clinic
syndrom
repres
plasma
cell
neoplasm
includ
multipl
myeloma
igm
waldenstrom
macroglobulinemia
solitari
plasmacytoma
includ
solitari
osseou
plasmacytoma
extramedullari
plasmacytoma
base
incid
sever
multipl
myeloma
clinic
import
plasma
cell
neoplasm
although
multipl
myeloma
mm
repres
fewer
malign
tumor
anim
account
approxim
hematopoiet
tumor
primari
secondari
tumor
affect
bone
dog
earli
studi
indic
male
predisposit
subsequ
report
suggest
gender
predilect
dog
older
dog
affect
often
averag
age
year
one
larg
case
seri
german
shepherd
overrepres
base
hospit
popul
true
incid
mm
cat
unknown
although
much
rarer
diagnosi
speci
dog
mm
account
one
four
tumor
two
larg
compil
felin
malign
malign
hematolog
malign
anoth
report
mm
occur
age
cat
median
age
year
often
domest
shorthair
gender
predilect
consist
report
although
male
preponder
may
exist
mm
associ
coronaviru
felv
fiv
infect
etiolog
mm
part
unknown
genet
predisposit
molecular
aberr
viral
infect
chronic
immun
stimul
exposur
carcinogen
stimul
suggest
contribut
factor
support
famili
associ
cat
come
case
report
among
sibl
evid
exist
molecular
mechan
cellular
control
includ
overexpress
cell
cycl
control
compon
cyclin
see
chapter
receptor
tyrosin
kinas
dysregul
may
involv
canin
myeloma
plasma
cell
tumor
rodent
model
chronic
immun
stimul
exposur
implant
silicon
gel
associ
develop
mm
chronic
infect
prolong
hyposensit
therapi
human
viral
aleutian
diseas
mink
result
monoclon
gammopathi
small
percentag
case
work
agricultur
industri
petroleum
product
irradi
known
risk
factor
develop
mm
human
progress
solitari
plasma
cell
tumor
mm
report
dog
cat
singl
case
bcell
lymphoma
progress
mm
report
dog
patholog
natur
behavior
mm
system
prolifer
malign
plasma
cell
precursor
aris
clone
singl
cell
usual
involv
multipl
bone
marrow
site
malign
plasma
cell
vari
appear
histolog
section
cytolog
prepar
degre
differenti
rang
cell
resembl
normal
plasma
cell
late
stage
differenti
figur
larg
anaplast
round
cell
high
mitot
index
repres
earli
stage
differenti
cat
mm
plasma
cell
one
report
immatur
mark
atypia
includ
increas
size
multipl
nuclei
cleft
nuclei
anisocytosi
anisokaryosi
variabl
nucleustocytoplasm
ratio
decreas
chromatin
densiti
variabl
nucleoli
nearli
one
fourth
cell
flame
cell
morpholog
character
peripher
eosinophil
cytoplasm
process
malign
plasma
cell
typic
produc
overabund
singl
type
compon
immunoglobulin
refer
compon
figur
compon
may
repres
class
entir
immunoglobulin
portion
molecul
light
chain
benc
jone
protein
heavi
chain
heavi
chain
diseas
dog
compon
usual
repres
either
igg
iga
immunoglobulin
type
nearli
equal
incid
wherea
ratio
igg
iga
cat
approxim
compon
igm
type
term
macroglobulinemia
also
waldenstrom
macroglobulinemia
often
appli
sever
case
biclon
gammopathi
dog
cat
report
two
case
nonsecretori
mm
report
dog
rare
cryoglobulinemia
report
dog
mm
igm
macroglobulinemia
report
cat
igg
myeloma
cryoglobulin
paraprotein
insolubl
temperatur
requir
blood
collect
clot
perform
serum
separ
whole
blood
allow
clot
temperatur
protein
precipit
part
iv
specif
malign
small
anim
patient
clot
lost
pure
lightchain
compon
rare
report
dog
patholog
associ
mm
result
high
level
circul
compon
organ
bone
infiltr
neoplast
cell
associ
patholog
condit
includ
bone
diseas
bleed
diathesi
hyperviscos
syndrom
renal
diseas
hypercalcemia
immunodefici
subsequ
suscept
infect
cytopenia
secondari
myelophthisi
cardiac
failur
bone
lesion
isol
discret
osteolyt
lesion
includ
patholog
fractur
figur
diffus
osteopenia
figur
approxim
one
fourth
two
third
dog
mm
radiograph
evid
boni
lysi
diffus
osteoporosi
skelet
lesion
cat
mm
rare
report
older
literatur
recent
report
document
lesion
case
bone
engag
activ
hematopoiesi
commonli
affect
includ
vertebra
rib
pelvi
skull
proxim
distal
long
bone
skelet
lesion
rare
igm
waldenstrom
macrogammaglobulinemia
malign
cell
often
infiltr
spleen
liver
lymph
tissu
rather
bone
bleed
diathesi
result
one
combin
event
compon
may
interfer
coagul
inhibit
platelet
aggreg
releas
platelet
factor
caus
adsorpt
minor
clot
protein
gener
abnorm
fibrin
polymer
produc
function
decreas
calcium
approxim
one
third
dog
one
fourth
cat
clinic
evid
hemorrhag
dog
nearli
half
abnorm
prothrombin
pt
partial
thromboplastin
ptt
time
thrombocytopenia
may
also
play
role
bone
marrow
infiltr
signific
ie
myelophthisi
hyperviscos
syndrom
hv
repres
one
constel
clinicopatholog
abnorm
result
greatli
increas
serum
viscos
magnitud
viscos
chang
depend
type
size
shape
concentr
compon
blood
hv
common
igm
macroglobulinemia
high
molecular
weight
class
immunoglobulin
iga
myeloma
usual
present
dimer
dog
may
undergo
polymer
result
increas
serum
viscos
iggassoci
hv
also
occur
albeit
less
frequent
high
serum
viscos
occur
approxim
dog
mm
result
bleed
diathesi
neurolog
sign
eg
dementia
depress
seizur
activ
coma
ophthalm
abnorm
eg
dilat
tortuou
retin
vessel
retin
hemorrhag
figur
retin
detach
increas
cardiac
workload
potenti
subsequ
develop
cardiomyopathi
consequ
thought
result
sludg
blood
small
vessel
ineffect
deliveri
oxygen
nutrient
coagul
abnorm
hv
report
less
commonli
cat
mm
older
literatur
report
associ
igg
iga
igmsecret
tumor
four
nine
cat
mm
rel
serum
viscos
control
rang
renal
diseas
present
approxim
one
third
one
half
dog
mm
azotemia
observ
refer
one
third
cat
one
report
pathogenesi
renal
failur
often
multifactori
develop
result
benc
jone
lightchain
proteinuria
tumor
infiltr
renal
tissu
hypercalcemia
amyloidosi
diminish
perfus
secondari
hyperviscos
syndrom
dehydr
ascend
urinari
tract
infect
normal
heavychain
lightchain
synthesi
well
balanc
nonneoplast
immunoglobulin
product
mm
unbalanc
excess
lightchain
product
may
result
light
chain
low
molecular
weight
normal
filter
renal
glomerulu
presenc
result
protein
precipit
subsequ
renal
tubular
injuri
presenc
light
chain
urin
without
concomit
monoclon
spike
serum
although
rare
indic
pure
lightchain
diseas
tubul
becom
obstruct
larg
lamin
cast
contain
albumin
immunoglobulin
light
chain
benc
jone
proteinuria
occur
approxim
dog
mm
two
recent
survey
occur
approxim
case
hypercalcemia
report
dog
mm
thought
result
primarili
product
osteoclastactiv
factor
neoplast
cell
factor
implic
human
mm
includ
elev
level
variou
cytokin
tnf
two
dog
mm
hypercalcemia
serum
elev
circul
ntermin
pthrp
note
hypercalcemia
may
also
exacerb
associ
renal
diseas
initi
thought
rare
event
cat
mm
hypercalcemia
note
recent
report
case
suscept
infect
immunodefici
long
associ
mm
often
ultim
caus
death
affect
anim
b
radiograph
distal
femur
dog
sever
osteolysi
patholog
fractur
secondari
plasma
cell
tumor
b
radiograph
patholog
fractur
surgic
repair
rush
rod
bone
cement
local
site
treat
adjuv
radiat
dog
continu
chemotherapi
year
well
infect
rate
human
mm
time
higher
normal
usual
repres
pneumonia
urinari
tract
infect
respons
vaccin
also
shown
suppress
human
mm
normal
immunoglobulin
level
often
sever
depress
affect
anim
addit
leukopenia
may
develop
secondari
myelophthisi
variabl
cytopenia
may
observ
associ
mm
approxim
two
third
dog
mm
normocyt
normochrom
nonregen
anemia
result
marrow
infiltr
myelophthisi
blood
loss
coagul
disord
anemia
chronic
diseas
increas
erythrocyt
destruct
secondari
high
serum
viscos
dog
mm
similar
factor
lead
thrombocytopenia
nearli
one
third
dog
leukopenia
nearli
one
fourth
cat
approxim
two
third
anem
one
half
thrombocytopen
one
third
neutropen
cardiac
diseas
present
usual
result
excess
cardiac
workload
myocardi
hypoxia
secondari
hyperviscos
myocardi
infiltr
amyloid
anemia
may
complic
factor
one
report
nearli
half
cat
mm
cardiac
murmur
etiolog
establish
clinic
sign
mm
may
present
year
diagnosi
dog
median
month
one
cat
mcompon
elev
detect
year
clinic
present
latter
case
mcompon
elev
consist
monoclon
gammopathi
unknown
signific
mgu
mgu
ie
benign
essenti
idiopath
monoclon
gammopathi
benign
monoclon
gammopathi
associ
osteolysi
bone
marrow
infiltr
benc
jone
proteinuria
mgu
also
report
dog
sign
mm
vari
depend
wide
rang
possibl
patholog
effect
tabl
multipl
retin
hemorrhag
fundu
cat
hyperviscos
syndrom
secondari
multipl
myeloma
sever
report
bleed
diathesi
usual
repres
epistaxi
gingiv
bleed
funduscop
abnorm
may
includ
retin
hemorrhag
see
figur
venou
dilat
saccul
tortuos
retin
detach
blind
cn
sign
may
includ
dementia
seizur
activ
defici
midbrain
brainstem
local
reflex
secondari
hv
extrem
hypercalcemia
sign
reflect
transvers
myelopathi
secondari
vertebr
column
infiltr
patholog
fractur
extradur
mass
compress
also
occur
one
case
ataxia
seizur
activ
dog
extramedullari
plasmacytoma
emp
secondari
tumorassoci
hypoglycemia
report
addit
paraneoplast
polyneuropathi
report
dog
mm
histori
chronic
respiratori
infect
persist
fever
may
also
present
cat
hepatosplenomegali
renomegali
occur
result
organ
infiltr
bleed
diathesi
due
hv
less
common
cat
epistaxi
pleural
periton
hemorrhag
effus
retin
hemorrhag
central
neurolog
sign
report
polydipsia
polyuria
occur
secondari
renal
diseas
hypercalcemia
dehydr
may
develop
hind
limb
paresi
secondari
osteolysi
lumbar
vertebr
bodi
extradur
compress
report
cat
diagnosi
mm
usual
follow
demonstr
bone
marrow
plasmacytosi
see
figur
presenc
osteolyt
bone
lesion
see
figur
demonstr
serum
urin
myeloma
protein
compon
see
figur
absenc
osteolyt
bone
lesion
diagnosi
also
made
marrow
plasmacytosi
associ
progress
increas
compon
cat
degre
bone
marrow
infiltr
may
mark
suggest
consider
plasma
cell
morpholog
viscer
organ
infiltr
case
demonstr
mcompon
diseas
absenc
mark
marrow
plasmacytosi
less
anim
suspect
plasma
cell
tumor
receiv
minim
diagnost
evalu
includ
cbc
platelet
count
serum
biochemistri
profil
urinalysi
particular
attent
paid
renal
function
serum
calcium
level
serum
electrophoresi
immunoelectrophoresi
perform
detect
monoclon
spike
see
figur
categor
immunoglobulin
class
involv
heat
precipit
electrophoresi
urin
perform
detect
benc
jone
proteinuria
commerci
urin
dipstick
method
capabl
determin
definit
diagnosi
usual
done
bone
marrow
aspir
bone
marrow
core
biopsi
multipl
aspir
may
necessari
possibl
cluster
plasma
cell
bone
marrow
normal
marrow
contain
fewer
plasma
cell
wherea
myelomatoid
marrow
level
often
greatli
exceed
current
recommend
requir
presenc
marrow
plasmacytosi
greater
howev
cutoff
cat
recent
recommend
special
attent
cellular
atypia
patel
colleagu
comment
even
threshold
problemat
cellular
atypia
viscer
organ
involv
consid
equal
import
routin
thorac
abdomin
radiograph
recommend
occasion
boni
lesion
observ
skelet
area
standard
film
organomegali
liver
spleen
kidney
observ
cat
figur
abdomin
ultrasound
scan
recommend
cat
suspect
mm
reveal
one
abdomin
tumor
nearli
patient
includ
splenomegali
without
nodul
diffus
hyperecho
hepatomegali
without
nodul
renomegali
iliac
lymph
node
enlarg
skelet
survey
radiograph
recommend
detect
determin
extent
osteolyt
lesion
may
diagnost
prognost
therapeut
implic
nuclear
scintigraphi
bone
scan
clinic
stage
dog
mm
perform
howev
predomin
osteolyt
activ
osteoblast
inact
scan
seldom
give
posit
result
therefor
use
routin
diagnosi
physicianbas
oncolog
bone
miner
densiti
analysi
dexa
scan
document
osteoporosi
mri
scan
bone
marrow
commonli
use
stage
howev
neither
appli
consist
veterinari
literatur
rare
case
biopsi
osteolyt
lesion
ie
jamshidi
core
biopsi
see
chapter
necessari
diagnosi
one
case
mm
dog
splenic
aspir
diagnost
help
clinic
hemorrhag
present
coagul
assess
eg
platelet
count
pt
ptt
serum
viscos
measur
done
anim
undergo
care
funduscop
examin
tabl
show
overal
frequenc
clinic
diagnost
abnorm
dog
cat
mm
compil
publish
seri
involv
least
five
case
clinic
stage
system
canin
mm
suggest
howev
current
prognost
signific
attribut
molecular
diagnost
techniqu
mm
limit
use
thu
far
veterinari
oncolog
howev
pcr
techniqu
use
determin
clonal
immunoglobulin
heavychain
variabl
region
gene
felin
plasmacytoma
myeloma
see
section
chapter
figur
use
technolog
case
diagnosi
straightforward
await
investig
diseas
syndrom
plasma
cell
tumor
associ
monoclon
gammopathi
consid
list
differenti
includ
lymphoreticular
tumor
lymphoma
extramedullari
plasmacytoma
chronic
acut
lymphocyt
leukemia
chronic
infect
eg
ehrlichiosi
leishmaniasi
fip
mgu
therapi
mm
direct
tumor
cell
mass
secondari
system
effect
diagnost
procedur
complet
primari
therapi
start
ensur
complet
diagnosi
procur
baselin
valu
monitor
respons
dog
mm
chemotherapi
effect
reduc
myeloma
cell
burden
reliev
bone
pain
allow
skelet
heal
reduc
level
serum
immunoglobulin
also
greatli
extend
qualiti
durat
patient
live
complet
elimin
neoplast
myeloma
cell
rare
chemotherapeut
drug
current
avail
make
mm
gratifi
diseas
treat
clinician
client
howev
eventu
relaps
expect
one
half
cat
mm
respond
chemotherapi
respons
shortliv
howev
sever
longterm
respons
ie
longer
year
report
treatment
attempt
educ
client
decid
therapeut
option
melphalan
alkyl
agent
chemotherapeut
drug
choic
treatment
mm
dog
initi
start
dosag
mgkg
given
oral
daili
day
reduc
mgkg
given
oral
daili
continu
addit
prednison
therapi
thought
increas
efficaci
melphalan
therapi
prednison
start
dosag
mgkg
given
oral
daili
day
reduc
mgkg
given
oral
everi
day
drug
discontinu
day
therapi
melphalan
howev
continu
mgkgday
clinic
relaps
occur
myelosuppress
necessit
dose
reduct
dog
treat
melphalanprednison
combin
toler
regimen
well
clinic
signific
toxic
melphalan
myelosuppress
particularli
delay
thrombocytopenia
cbc
includ
platelet
count
perform
biweekli
month
therapi
monthli
thereaft
signific
myelosuppress
occur
usual
thrombocytopenia
neutropenia
dosag
treatment
frequenc
may
need
reduc
author
success
use
altern
pulsedos
regimen
melphalan
mgm
given
oral
daili
consecut
day
everi
week
small
number
case
myelosuppress
limit
convent
continu
lowdos
therapi
author
use
pulsedos
regimen
firstlin
treatment
caveat
longterm
respons
data
lack
melphalanprednison
therapi
also
use
cat
mm
howev
protocol
appear
myelosuppress
cat
dog
care
monitor
requir
cat
dose
schedul
similar
dog
report
mgkg
approxim
mg
mg
tablet
given
oral
daili
day
everi
day
clinic
improv
occur
leukopenia
develop
one
report
advoc
longterm
continu
mainten
mgkg
given
oral
everi
day
cyclophosphamid
use
altern
alkyl
agent
combin
melphalan
dog
mm
evid
indic
superior
melphalan
therapi
author
practic
cyclophosphamid
limit
patient
sever
hypercalcemia
widespread
system
involv
faster
act
alkyl
agent
may
allevi
system
effect
quickli
cyclophosphamid
initi
dosag
mgm
given
intraven
time
oral
melphalan
therapi
start
cyclophosphamid
less
like
affect
thrombocyt
may
substitut
patient
thrombocytopenia
develop
secondari
longterm
melphalan
use
chlorambucil
anoth
alkyl
agent
use
success
treatment
igm
macroglobulinemia
dog
dosag
mgkg
given
oral
daili
clinic
sign
toxic
result
dose
schedul
ccnu
yet
anoth
alkyl
agent
use
limit
number
cat
mm
partial
respons
report
dose
schedul
mgm
given
oral
everi
day
evalu
respons
therapi
evalu
respons
system
therapi
mm
base
improv
clinic
sign
clinicopatholog
paramet
radiograph
improv
skelet
lesion
subject
improv
clinic
sign
bone
pain
lame
lethargi
anorexia
evid
within
week
initi
therapi
object
laboratori
improv
includ
reduct
serum
immunoglobulin
benc
jone
proteinuria
usual
note
within
week
radiograph
improv
osteolyt
bone
lesion
may
take
month
partial
resolut
may
occur
ophthalm
complic
includ
longstand
retin
detach
paraneoplast
neuropathi
expect
resolv
along
tumor
mass
one
report
cat
respond
melphalan
prednison
clinic
improv
note
week
serum
protein
radiograph
bone
abnorm
greatli
improv
week
previous
discuss
mm
resolv
complet
good
respons
defin
reduct
measur
compon
ie
immunoglobulin
benc
jone
protein
least
pretreat
valu
reduct
serum
immunoglobulin
level
may
lag
behind
reduct
benc
jone
proteinuria
halfliv
day
hour
respect
routin
followup
quantif
elev
serum
immunoglobulin
urin
benc
jone
protein
perform
monthli
good
respons
note
everi
month
repeat
bone
marrow
aspir
evalu
plasma
cell
infiltr
occasion
may
necessari
particularli
prudent
cytopenia
develop
chemotherapi
drug
toxic
must
differenti
marrow
recurr
longterm
control
complic
hypercalcemia
hv
bleed
diathesi
renal
diseas
immunosuppress
ophthalm
complic
patholog
skelet
fractur
achiev
control
primari
tumor
mass
howev
therapi
direct
specif
complic
may
indic
short
term
hypercalcemia
mark
signific
clinic
sign
present
standard
therapi
includ
fluid
diures
without
pharmacolog
agent
eg
calcitonin
may
indic
see
chapter
moder
hypercalcemia
typic
resolv
within
day
initi
melphalanprednison
chemotherapi
hv
best
treat
short
term
plasmapheresi
whole
blood
collect
patient
centrifug
separ
plasma
pack
cell
pack
red
cell
resuspend
normal
salin
reinfus
patient
bleed
diathesi
usual
resolv
along
hv
plateletrich
plasma
transfus
may
necessari
thrombocytopenia
renal
impair
may
requir
aggress
fluid
therapi
short
term
mainten
adequ
hydrat
long
term
care
attent
secondari
urinari
tract
infect
appropri
antimicrobi
therapi
indic
ensur
adequ
water
intak
home
import
case
owner
must
taught
home
subcutan
fluid
administr
continu
monitor
renal
function
recommend
along
followup
direct
tumor
respons
patient
mm
thought
immunolog
crippl
recommend
prophylact
antibiot
therapi
dog
mm
human
benefit
approach
observ
dilig
monitor
aggress
antimicrobi
manag
indic
cidal
antimicrobi
prefer
static
drug
nephrotox
antimicrobi
use
patholog
fractur
weightbear
long
bone
vertebra
result
spinal
cord
compress
may
requir
immedi
intervent
conjunct
system
chemotherapi
orthoped
stabil
fractur
perform
may
follow
extern
beam
radiotherapi
see
figur
b
recent
inhibit
osteoclast
activ
bisphosphon
drug
shown
reduc
incid
sever
skelet
complic
mm
human
class
drug
may
hold
promis
use
dog
cat
variou
skelet
tumor
rescu
therapi
may
attempt
mm
eventu
relaps
dog
undergo
melphalan
therapi
uncommon
patient
initi
resist
alkyl
agent
author
success
vad
protocol
combin
doxorubicin
mgm
given
intraven
everi
day
vincristin
mgm
given
intraven
day
dexamethason
sodium
phosphat
mgkg
given
intraven
week
day
regimen
use
cycl
although
dog
initi
respond
rescu
protocol
durat
respons
tend
short
last
month
highdos
cyclophosphamid
mgm
given
intraven
everi
day
also
use
rescu
agent
although
limit
success
liposom
doxorubicin
produc
longterm
remiss
dog
mm
resist
nativ
doxorubicin
mm
ultim
uniformli
fatal
diseas
speci
includ
human
signific
effort
put
investig
therapi
diseas
current
bone
marrow
abl
therapi
marrow
stem
cell
rescu
thalidomid
antiangiogen
therapi
bortezomib
proteasom
inhibitor
arsen
trioxid
bisphosphon
sever
molecular
target
therapi
investig
howev
use
veterinari
speci
limit
complet
absent
present
nonetheless
promis
moleculartarget
therapi
foreshadow
case
dog
mm
resist
melphalan
prednison
doxorubicin
dog
achiev
partial
respons
tyrosin
kinas
inhibitor
therapi
see
chapter
section
b
maintain
month
prognosi
dog
mm
good
initi
control
tumor
return
good
qualiti
life
group
dog
mm
approxim
achiev
complet
remiss
ie
normal
serum
immunoglobulin
achiev
partial
remiss
ie
immunoglobulin
level
less
pretreat
valu
respond
melphalanprednison
chemotherapi
longterm
surviv
norm
median
day
report
figur
hypercalcemia
benc
jone
proteinuria
extens
boni
lysi
known
neg
prognost
indic
dog
longterm
prognosi
dog
mm
poor
recurr
tumor
mass
associ
clinic
sign
expect
eventu
tumor
longer
respond
avail
chemotherapeut
drug
death
follow
renal
failur
sepsi
euthanasia
intract
bone
spinal
pain
prognosi
mm
cat
favor
short
term
dog
although
cat
approxim
transient
respond
melphalanprednisoneor
cyclophosphamidebas
protocol
respons
partial
durabl
typic
cat
mm
succumb
diseas
within
month
howev
longterm
survivor
longer
year
report
one
investig
group
mm
cat
two
prognost
categori
base
criteria
known
predict
diseas
behavior
dog
tabl
although
rigor
statist
analysi
perform
small
group
cat
nine
median
surviv
time
day
cat
diseas
categor
aggress
day
diseas
categor
nonaggress
experi
dog
igm
macroglobulinemia
limit
respons
chlorambucil
expect
nine
treat
dog
achiev
remiss
median
surviv
time
month
solitari
collect
monoclon
plasmacyt
tumor
origin
soft
tissu
extramedullari
plasmacytoma
bone
solitari
osseou
plasmacytoma
sop
number
larg
case
compil
cutan
plasmacytoma
report
dog
plasmacytoma
repres
canin
tumor
submiss
one
larg
compil
case
seri
case
common
locat
dog
cutan
site
figur
mucou
membran
oral
caviti
lip
figur
rectum
colon
skin
limb
head
includ
ear
frequent
report
cutan
site
site
account
remain
case
site
may
includ
stomach
spleen
genitalia
eye
uteru
liver
american
cocker
spaniel
english
cocker
spaniel
west
highland
white
terrier
perhap
yorkshir
terrier
boxer
german
shepherd
airedal
terrier
increas
risk
develop
plasmacytoma
median
age
affect
dog
year
cutan
oral
emp
dog
typic
manifest
benign
tumor
highli
amen
local
therapi
natur
behavior
noncutaneousnonor
emp
appear
somewhat
aggress
dog
gastrointestin
emp
report
number
site
veterinari
literatur
includ
esophagu
stomach
figur
small
intestin
larg
intestin
metastasi
associ
lymph
node
common
case
howev
bone
marrow
involv
monoclon
gammopathi
less
commonli
encount
nine
case
colorect
emp
two
dog
experienc
recurr
surgic
excis
two
case
involv
multipl
lesion
emp
trachea
liver
uteru
also
report
dog
benign
cours
local
resect
case
sop
eventu
progress
system
mm
howev
time
cours
local
tumor
develop
system
mm
may
mani
month
year
sop
report
dog
involv
zygomat
arch
rib
plasmacytoma
less
common
cat
fewer
report
exist
literatur
occur
older
cat
mean
age
year
signific
gender
predilect
skin
common
site
site
includ
oral
caviti
eye
gi
tract
liver
subcutan
tissu
brain
two
report
exist
cutan
emp
cat
progress
system
diseas
one
cat
develop
lymph
node
distant
metastasi
progress
mm
cutan
plasmacytoma
limb
dog
clinic
sign
associ
solitari
plasmacytoma
relat
locat
involv
rare
case
involv
high
level
compon
hv
may
occur
cutan
plasmacytoma
solitari
smooth
rais
pink
nodul
measur
cm
diamet
see
figur
although
tumor
larg
cm
report
combin
data
larg
seri
show
tumor
occur
solitari
mass
fewer
occur
part
system
mm
process
cutan
oral
form
emp
usual
benign
cours
relat
clinic
sign
gastrointestin
emp
howev
typic
produc
rel
nonspecif
sign
may
suggest
alimentari
involv
colorect
plasmacytoma
usual
caus
rectal
bleed
hematochezia
tenesmu
rectal
prolaps
one
case
ataxia
seizur
activ
dog
emp
secondari
tumorassoci
hypoglycemia
report
sop
usual
associ
pain
lame
appendicular
skeleton
affect
neurolog
sign
vertebr
bodi
involv
diagnosi
sop
emp
usual
requir
tissu
biopsi
fineneedl
aspir
cell
make
b
solitari
plasmacyt
tumor
cat
dog
classifi
histolog
matur
hyalin
cleav
asynchron
monomorph
blastic
polymorph
blastic
cell
type
prognost
signific
observ
classif
system
although
suggest
polymorph
blastic
type
may
act
aggress
dog
poorli
differenti
solitari
plasmacyt
tumor
immunohistochem
studi
direct
detect
immunoglobulin
light
heavi
chain
thioflavin
may
help
differenti
lesion
round
cell
tumor
immunoreact
demonstr
canin
igg
f
ab
vimentin
variant
character
iggreact
amyloid
interspers
neoplast
cell
also
describ
addit
pcr
techniqu
use
determin
clonal
immunoglobulin
heavychain
variabl
region
gene
plasmacytoma
myeloma
may
diagnost
use
difficult
case
thorough
stage
import
dog
cat
plasmacytoma
higher
risk
system
spread
stage
must
done
therapi
start
includ
bone
marrow
aspir
serum
electrophoresi
skelet
survey
radiograph
ensur
diseas
confin
local
site
import
sop
gastrointestin
emp
tumor
rel
high
metastat
rate
less
import
cutan
oral
plasmacytoma
typic
benign
behavior
addit
endoscop
evalu
entir
gi
tract
recommend
gastrointestin
emp
cutan
plasma
cell
tumor
dog
almost
alway
benign
excel
prognosi
conserv
surgic
excis
success
therapi
melphalan
prednison
rare
appli
local
recurr
incomplet
margin
dog
cat
radiat
therapi
use
infrequ
case
nonsurg
surgeri
recommend
combin
radiotherapi
sop
lesion
result
unstabl
long
bone
fractur
see
patient
nonambulatori
neurolog
compromis
caus
vertebr
bodi
sop
latter
case
spinal
cord
decompress
mass
excis
possibl
spinal
stabil
may
necessari
radiotherapi
use
without
surgeri
fractur
stabl
palli
measur
bone
pain
case
vertebr
sop
patient
ambulatori
stabl
good
local
control
usual
achiev
patient
eventu
develop
system
mm
sop
axial
skeleton
manag
excis
radiotherapi
alon
whether
system
chemotherapi
initi
time
local
therapi
sop
system
involv
document
subject
debat
system
spread
may
occur
mani
month
even
year
beyond
primari
sop
diagnosi
human
dog
studi
human
reveal
benefit
initi
system
chemotherapi
document
subsequ
system
spread
similarli
emp
gi
tract
human
often
treat
surgic
excis
thorough
stage
diseas
system
therapi
initi
unless
system
involv
document
system
chemotherapi
use
follow
excis
gastric
emp
cat
util
adjuv
therapi
speci
unkown
longterm
followup
patient
solitari
plasmacytoma
indic
recurr
diseas
system
spread
recogn
patient
sop
care
attent
paid
serum
globulin
level
bone
pain
radiograph
appear
bone
heal
restag
diseas
includ
bone
marrow
evalu
indic
system
spread
suspect
prognosi
solitari
plasma
cell
tumor
gener
good
cutan
mucocutan
plasmacytoma
usual
cure
surgic
excis
larg
compil
case
dog
local
recurr
rate
approxim
nodal
distant
metastasi
occur
seven
case
new
cutan
plasmacytoma
site
distant
primari
tumor
develop
fewer
case
one
caveat
author
encount
hand
case
aggress
multipl
cutan
plasmacytoma
eventu
result
death
affect
dog
neither
tumor
cell
prolifer
rate
measur
immunohistochemistri
dog
histopatholog
grade
dog
cat
prognost
larg
compil
case
although
suggest
polymorph
blastic
type
may
act
aggress
dog
presenc
amyloid
overexpress
cyclin
prognost
human
plasmacytoma
shown
prognost
dog
dog
emp
alimentari
tract
abdomin
organ
eg
liver
uteru
treat
surgic
excis
alon
combin
system
chemotherapi
metastasi
present
enjoy
longterm
surviv
compil
nine
dog
colorect
plasmacytoma
two
local
recurr
month
surgeri
surgeri
alon
overal
median
surviv
time
month
dna
ploidi
cmyc
oncoprotein
express
biopsi
sampl
determin
predict
emp
dog
howev
tumor
malign
noncutan
site
ie
lymph
node
colon
spleen
therefor
locat
appear
predict
previous
discuss
